BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H, Tanwandee T, Tao QM, Shue K, Keene ON, Dixon JS, Gray DF, Sabbat J;  Cirrhosis Asian Lamivudine Multicentre Study Group. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med. 2004;351:1521-1531. [PMID: 15470215 DOI: 10.1056/nejmoa033364] [Cited by in Crossref: 1605] [Cited by in F6Publishing: 520] [Article Influence: 94.4] [Reference Citation Analysis]
Number Citing Articles
1 Rapti I, Hadziyannis S. Risk for hepatocellular carcinoma in the course of chronic hepatitis B virus infection and the protective effect of therapy with nucleos(t)ide analogues. World J Hepatol 2015; 7(8): 1064-1073 [PMID: 26052395 DOI: 10.4254/wjh.v7.i8.1064] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 4.7] [Reference Citation Analysis]
2 Venkatesh SK, Yin M, Ehman RL. Magnetic resonance elastography of liver: technique, analysis, and clinical applications. J Magn Reson Imaging. 2013;37:544-555. [PMID: 23423795 DOI: 10.1002/jmri.23731] [Cited by in Crossref: 354] [Cited by in F6Publishing: 318] [Article Influence: 44.3] [Reference Citation Analysis]
3 Matsumoto K, Miyake Y, Miyatake H, Takahara M, Imada T, Yagi S, Toyokawa T, Nakatsu M, Ando M, Hirohata M. A combination treatment of entecavir and early-phase corticosteroid in severe exacerbation of chronic hepatitis B. World J Gastroenterol 2009; 15(13): 1650-1652 [PMID: 19340912 DOI: 10.3748/wjg.15.1650] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
4 Hann HW, Coben R, Brown D, Needleman L, Rosato E, Min A, Hann RS, Park KB, Dunn S, DiMarino AJ. A long-term study of the effects of antiviral therapy on survival of patients with HBV-associated hepatocellular carcinoma (HCC) following local tumor ablation. Cancer Med. 2014;3:390-396. [PMID: 24519810 DOI: 10.1002/cam4.197] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 3.3] [Reference Citation Analysis]
5 Buti M, Tsai N, Petersen J, Flisiak R, Gurel S, Krastev Z, Aguilar Schall R, Flaherty JF, Martins EB, Charuworn P, Kitrinos KM, Subramanian GM, Gane E, Marcellin P. Seven-year efficacy and safety of treatment with tenofovir disoproxil fumarate for chronic hepatitis B virus infection. Dig Dis Sci. 2015;60:1457-1464. [PMID: 25532501 DOI: 10.1007/s10620-014-3486-7] [Cited by in Crossref: 173] [Cited by in F6Publishing: 155] [Article Influence: 24.7] [Reference Citation Analysis]
6 Kennedy PTF, Litwin S, Dolman GE, Bertoletti A, Mason WS. Immune Tolerant Chronic Hepatitis B: The Unrecognized Risks. Viruses 2017;9:E96. [PMID: 28468285 DOI: 10.3390/v9050096] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 7.8] [Reference Citation Analysis]
7 Lu T, Seto WK, Zhu RX, Lai CL, Yuen MF. Prevention of hepatocellular carcinoma in chronic viral hepatitis B and C infection. World J Gastroenterol 2013; 19(47): 8887-8894 [PMID: 24379612 DOI: 10.3748/wjg.v19.i47.8887] [Cited by in CrossRef: 28] [Cited by in F6Publishing: 23] [Article Influence: 3.5] [Reference Citation Analysis]
8 Yun TJ, Jung JY, Kim CH, Um SH, An H, Seo YS, Kim JD, Yim HJ, Keum B, Kim YS, Jeen YT, Lee HS, Chun HJ, Kim CD, Ryu HS. Treatment strategies using adefovir dipivoxil for individuals with lamivudine-resistant chronic hepatitis B. World J Gastroenterol 2012; 18(47): 6987-6995 [PMID: 23322998 DOI: 10.3748/wjg.v18.i47.6987] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
9 Mallet M, Rudler M, Thabut D. Variceal bleeding in cirrhotic patients. Gastroenterol Rep (Oxf). 2017;5:185-192. [PMID: 28852523 DOI: 10.1093/gastro/gox024] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 4.5] [Reference Citation Analysis]
10 Rockey DC. Liver Fibrosis Reversion After Suppression of Hepatitis B Virus. Clin Liver Dis. 2016;20:667-679. [PMID: 27742006 DOI: 10.1016/j.cld.2016.06.003] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
11 Nguyen T, Locarnini S. Hepatitis: Monitoring drug therapy for hepatitis B--a global challenge? Nat Rev Gastroenterol Hepatol. 2009;6:565-567. [PMID: 19789570 DOI: 10.1038/nrgastro.2009.160] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 0.8] [Reference Citation Analysis]
12 Villanueva A, Hoshida Y, Toffanin S, Lachenmayer A, Alsinet C, Savic R, Cornella H, Llovet JM. New strategies in hepatocellular carcinoma: genomic prognostic markers. Clin Cancer Res 2010;16:4688-94. [PMID: 20713493 DOI: 10.1158/1078-0432.CCR-09-1811] [Cited by in Crossref: 92] [Cited by in F6Publishing: 59] [Article Influence: 8.4] [Reference Citation Analysis]
13 Park CH, Jung SW, Shin JW, Bae MA, Lee YI, Park YT, Chung HS, Park NH. Comparison of tenofovir plus lamivudine versus tenofovir monotherapy in patients with lamivudine-resistant chronic hepatitis B. Clin Mol Hepatol 2016;22:152-9. [PMID: 27044766 DOI: 10.3350/cmh.2016.22.1.152] [Reference Citation Analysis]
14 Chang TS, Yang YH, Chen WM, Shen CH, Tung SY, Yen CW, Hsieh YY, Lee CP, Tsai ML, Hung CH, Lu SN. Long-term risk of primary liver cancers in entecavir versus tenofovir treatment for chronic hepatitis B. Sci Rep. 2021;11:1365. [PMID: 33446835 DOI: 10.1038/s41598-020-80523-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
15 Nitschmann S. [Treatment options in chronic hepatitis B]. Internist (Berl) 2006;47:308-9; discussion 309-10. [PMID: 16485097 DOI: 10.1007/s00108-005-1573-8] [Reference Citation Analysis]
16 Rodríguez M, Pascasio JM, Fraga E, Fuentes J, Prieto M, Sánchez-Antolín G, Calleja JL, Molina E, García-Buey ML, Blanco MÁ, Salmerón J, Bonet ML, Pons JA, González JM, Casado MÁ, Jorquera F, the TENOSIMP-B Research Group. Tenofovir vs lamivudine plus adefovir in chronic hepatitis B: TENOSIMP-B study. World J Gastroenterol 2017; 23(41): 7459-7469 [PMID: 29151700 DOI: 10.3748/wjg.v23.i41.7459] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
17 Lok AS, Zoulim F, Dusheiko G, Ghany MG. Hepatitis B cure: From discovery to regulatory approval. Hepatology. 2017;66:1296-1313. [PMID: 28762522 DOI: 10.1002/hep.29323] [Cited by in Crossref: 129] [Cited by in F6Publishing: 129] [Article Influence: 32.3] [Reference Citation Analysis]
18 Hall S, Howell J, Visvanathan K, Thompson A. The Yin and the Yang of Treatment for Chronic Hepatitis B-When to Start, When to Stop Nucleos(t)ide Analogue Therapy. Viruses 2020;12:E934. [PMID: 32854335 DOI: 10.3390/v12090934] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 7.0] [Reference Citation Analysis]
19 Lim TH, Gane E, Moyes C, Borman B, Cunningham C. HBsAg loss in a New Zealand community study with 28-year follow-up: rates, predictors and long-term outcomes. Hepatol Int. 2016;10:829-837. [PMID: 26957439 DOI: 10.1007/s12072-016-9709-6] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
20 Perrillo RP. Hepatitis B virus treatment: Which patients require immediate treatment. Clin Liver Dis (Hoboken) 2013;2:11-4. [PMID: 30992812 DOI: 10.1002/cld.140] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
21 Liu KZ, Hou W, Zumbika E, Ni Q. Clinical features of chronic hepatitis B patients with YMDD mutation after lamivudine therapy. J Zhejiang Univ Sci B. 2005;6:1182-1187. [PMID: 16358376 DOI: 10.1631/jzus.2005.B1182] [Cited by in Crossref: 10] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
22 Wu YL, Shen CL, Chen XY. Antiviral treatment for chronic hepatitis B: Safety, effectiveness, and prognosis. World J Clin Cases 2019; 7(14): 1784-1794 [PMID: 31417924 DOI: 10.12998/wjcc.v7.i14.1784] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
23 Chung GE, Lee JH, Kim YJ. Does antiviral therapy reduce complications of cirrhosis? World J Gastroenterol 2014; 20(23): 7306-7311 [PMID: 24966601 DOI: 10.3748/wjg.v20.i23.7306] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
24 Singal AG, El-Serag HB. Hepatocellular Carcinoma From Epidemiology to Prevention: Translating Knowledge into Practice. Clin Gastroenterol Hepatol. 2015;13:2140-2151. [PMID: 26284591 DOI: 10.1016/j.cgh.2015.08.014] [Cited by in Crossref: 269] [Cited by in F6Publishing: 274] [Article Influence: 44.8] [Reference Citation Analysis]
25 Schütte K, Balbisi F, Malfertheiner P. Prevention of Hepatocellular Carcinoma. Gastrointest Tumors 2016;3:37-43. [PMID: 27722155 DOI: 10.1159/000446680] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]
26 Vu VD, Do A, Nguyen NH, Kim LH, Trinh HN, Nguyen HA, Nguyen KK, Nguyen M, Huynh A, Nguyen MH. Long-term follow-up and suboptimal treatment rates of treatment-eligible chronic hepatitis B patients in diverse practice settings: a gap in linkage to care. BMJ Open Gastroenterol 2015;2:e000060. [PMID: 26543565 DOI: 10.1136/bmjgast-2015-000060] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
27 Huang H, Sun Z, Pan H, Chen M, Tong Y, Zhang J, Chen D, Su X, Li L. Serum metabolomic signatures discriminate early liver inflammation and fibrosis stages in patients with chronic hepatitis B. Sci Rep 2016;6:30853. [PMID: 27498553 DOI: 10.1038/srep30853] [Cited by in Crossref: 10] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
28 Robinson DM, Scott LJ, Plosker GL. Entecavir: a review of its use in chronic hepatitis B. Drugs. 2006;66:1605-122; discussion 1605-122;. [PMID: 16956310 DOI: 10.2165/00003495-200666120-00009] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 1.3] [Reference Citation Analysis]
29 Li S, Saviano A, Erstad DJ, Hoshida Y, Fuchs BC, Baumert T, Tanabe KK. Risk Factors, Pathogenesis, and Strategies for Hepatocellular Carcinoma Prevention: Emphasis on Secondary Prevention and Its Translational Challenges. J Clin Med 2020;9:E3817. [PMID: 33255794 DOI: 10.3390/jcm9123817] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
30 Mah A, Wright A. Infectious Considerations in the Pre-Transplant Evaluation of Cirrhotic Patients Awaiting Orthotopic Liver Transplantation. Curr Infect Dis Rep. 2016;18:4. [PMID: 26743200 DOI: 10.1007/s11908-015-0514-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
31 Leemans W, Janssen H, de Man R. Future prospectives for the management of chronic hepatitis B. World J Gastroenterol 2007; 13(18): 2554-2567 [PMID: 17552002 DOI: 10.3748/wjg.v13.i18.2554] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 22] [Article Influence: 1.2] [Reference Citation Analysis]
32 Woo HY, Choi JY, Yoon SK, Suh DJ, Paik SW, Han KH, Um SH, Kim BI, Lee HJ, Cho M, Lee CK, Kim DJ, Hwang JS. Rescue therapy with adefovir in decompensated liver cirrhosis patients with lamivudine-resistant hepatitis B virus. Clin Mol Hepatol 2014;20:168-76. [PMID: 25032183 DOI: 10.3350/cmh.2014.20.2.168] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
33 Liaw YF, Leung N, Kao JH, Piratvisuth T, Gane E, Han KH, Guan R, Lau GK, Locarnini S. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int. 2008;2:263-283. [PMID: 19669255 DOI: 10.1007/s12072-008-9080-3.] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
34 Tian N, Liu Z, Yang M, Li Z, Zhang G, Han Q, Li N, Zhu Q, Lv Y, Wang Y, Xing F. Effect of antiviral therapy on the survival and incidence of major complications in HBV-associated cirrhotic patients after splenectomy for hypersplenism and portal hypertension. Virol J 2012;9:273. [PMID: 23158807 DOI: 10.1186/1743-422X-9-273] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
35 Zamor PJ, deLemos AS, Russo MW. Viral hepatitis and hepatocellular carcinoma: etiology and management. J Gastrointest Oncol 2017;8:229-42. [PMID: 28480063 DOI: 10.21037/jgo.2017.03.14] [Cited by in Crossref: 60] [Cited by in F6Publishing: 55] [Article Influence: 15.0] [Reference Citation Analysis]
36 Lovett GC, Nguyen T, Iser DM, Holmes JA, Chen R, Demediuk B, Shaw G, Bell SJ, Desmond PV, Thompson AJ. Efficacy and safety of tenofovir in chronic hepatitis B: Australian real world experience. World J Hepatol 2017; 9(1): 48-56 [PMID: 28105258 DOI: 10.4254/wjh.v9.i1.48] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
37 Kawanaka M, Nishino K, Nakamura J, Oka T, Urata N, Goto D, Suehiro M, Kawamoto H, Kudo M, Yamada G. Quantitative Levels of Hepatitis B Virus DNA and Surface Antigen and the Risk of Hepatocellular Carcinoma in Patients with Hepatitis B Receiving Long-Term Nucleos(t)ide Analogue Therapy. Liver Cancer. 2014;3:41-52. [PMID: 24804176 DOI: 10.1159/000343857] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 3.0] [Reference Citation Analysis]
38 McCaughan GW. Prevention of post liver transplant HBV recurrence. Hepatol Int. 2011; Aug 10. [Epub ahead of print]. [PMID: 22020819 DOI: 10.1007/s12072-011-9293-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
39 Kanda T, Ogasawara S, Chiba T, Haga Y, Omata M, Yokosuka O. Current management of patients with hepatocellular carcinoma. World J Hepatol 2015; 7(15): 1913-1920 [PMID: 26244066 DOI: 10.4254/wjh.v7.i15.1913] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 4.7] [Reference Citation Analysis]
40 Zoulim F. Hepatitis B virus resistance to antiviral drugs: where are we going? Liver Int. 2011;31 Suppl 1:111-116. [PMID: 21205147 DOI: 10.1111/j.1478-3231.2010.02399.x] [Cited by in Crossref: 78] [Cited by in F6Publishing: 82] [Article Influence: 7.8] [Reference Citation Analysis]
41 Xie F, Yan L, Lu J, Zheng T, Shi C, Ying J, Shen R, Yang J. Effects of nucleoside analogue on patients with chronic hepatitis B-associated liver failure: meta-analysis. PLoS One. 2013;8:e54773. [PMID: 23382964 DOI: 10.1371/journal.pone.0054773] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 2.4] [Reference Citation Analysis]
42 Robotin M, Patton Y, Kansil M, Penman A, George J. Cost of treating chronic hepatitis B: Comparison of current treatment guidelines. World J Gastroenterol 2012; 18(42): 6106-6113 [PMID: 23155339 DOI: 10.3748/wjg.v18.i42.6106] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
43 Hoffmeister A, Schiefke I, Teich N, Mössner J, Schoppmeyer K. [Prevention of gastrointestinal malignancies]. Internist (Berl) 2008;49:178-84. [PMID: 18210023 DOI: 10.1007/s00108-007-1998-3] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
44 Perrillo RP, Hann HW, Schiff E, Mutimer D, Willems B, Leung N, Lee WM, Dixon S, Woessner M, Brosgart CL, Condreay LD, Gardner SD. Extended treatment with lamivudine and adefovir dipivoxil in chronic hepatitis B patients with lamivudine resistance. Hepatol Int 2011;5:654-63. [PMID: 21484148 DOI: 10.1007/s12072-010-9228-9] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
45 Karino Y, Toyota J, Kumada H, Katano Y, Izumi N, Kobashi H, Sata M, Moriyama M, Imazeki F, Kage M. Efficacy and resistance of entecavir following 3 years of treatment of Japanese patients with lamivudine-refractory chronic hepatitis B. Hepatol Int. 2010;4:414-422. [PMID: 20305760 DOI: 10.1007/s12072-009-9162-x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 1.5] [Reference Citation Analysis]
46 Zhong JH. Nucleos(t)ide analogue therapy for HBV-related HCC after hepatic resection: clinical benefits and unanswered questions. Tumour Biol. 2014;35:12779-12784. [PMID: 25431264 DOI: 10.1007/s13277-014-2881-1] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
47 Chang TT. On-treatment monitoring of HBV DNA levels: predicting response and resistance to oral antiviral therapy at week 24 versus week 48. Hepatol Int 2009;3 Suppl 1:16-23. [PMID: 19669242 DOI: 10.1007/s12072-009-9143-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
48 Brouwer WP, Chan HLY, Lampertico P, Hou J, Tangkijvanich P, Reesink HW, Zhang W, Mangia A, Tanwandee T, Montalto G, Simon K, Ormeci N, Chen L, Tabak F, Gunsar F, Flisiak R, Ferenci P, Akdogan M, Akyuz F, Hirankarn N, Jansen L, Wong VW, Soffredini R, Liang X, Chen S, Groothuismink ZMA, Santoro R, Jaroszewicz J, Ozaras R, Kozbial K, Brahmania M, Xie Q, Chotiyaputta W, Xun Q, Pazgan-Simon M, Oztas E, Verhey E, Montanari NR, Sun J, Hansen BE, Boonstra A, Janssen HLA; GIANT-B Global Consortium. Genome-wide Association Study Identifies Genetic Variants Associated With Early and Sustained Response to (Pegylated) Interferon in Chronic Hepatitis B Patients: The GIANT-B Study. Clin Infect Dis 2019;69:1969-79. [PMID: 30715261 DOI: 10.1093/cid/ciz084] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
49 Yao G, Chen C, Lu W, Ren H, Tan D, Wang Y, Xu D, Jiang Z, Liu J, Xu D. Efficacy and safety of entecavir compared to lamivudine in nucleoside-naïve patients with chronic hepatitis B: a randomized double-blind trial in China. Hepatol Int. 2007;1:365-372. [PMID: 19669331 DOI: 10.1007/s12072-007-9009-2] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 2.3] [Reference Citation Analysis]
50 Cuestas ML, Mathet VL, Oubiña JR, Sosnik A. Drug delivery systems and liver targeting for the improved pharmacotherapy of the hepatitis B virus (HBV) infection. Pharm Res 2010;27:1184-202. [PMID: 20333454 DOI: 10.1007/s11095-010-0112-z] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 1.9] [Reference Citation Analysis]
51 Mittal S, El-Serag HB. Epidemiology of hepatocellular carcinoma: consider the population. J Clin Gastroenterol. 2013;47 Suppl:S2-S6. [PMID: 23632345 DOI: 10.1097/mcg.0b013e3182872f29.epidemiology] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
52 Schiff ER. Antiviral therapy in patients with chronic hepatitis B and hepatocellular carcinoma: post-thermal ablation. Better late than never? Hepatol Int 2008;2:1-2. [PMID: 19669274 DOI: 10.1007/s12072-007-9036-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
53 Abdo AA, Hassanain M, AlJumah A, Al Olayan A, Sanai FM, Alsuhaibani HA, Abdulkareem H, Abdallah K, AlMuaikeel M, Al Saghier M, Babatin M, Kabbani M, Bazarbashi S, Metrakos P, Bruix J; Saudi Association for the Study of Liver Diseases and Transplantation., Saudi Oncology Society. Saudi guidelines for the diagnosis and management of hepatocellular carcinoma: technical review and practice guidelines. Ann Saudi Med 2012;32:174-99. [PMID: 22366832 DOI: 10.5144/0256-4947.2012.174] [Cited by in Crossref: 13] [Cited by in F6Publishing: 17] [Article Influence: 1.6] [Reference Citation Analysis]
54 Kim WR, Terrault NA, Pedersen RA, Therneau TM, Edwards E, Hindman AA, Brosgart CL. Trends in waiting list registration for liver transplantation for viral hepatitis in the United States. Gastroenterology. 2009;137:1680-1686. [PMID: 19632234 DOI: 10.53/j.gastro.2009.07.047] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
55 Cho WH, Lee HJ, Bang KB, Kim SB, Song IH. Development of tenofovir disoproxil fumarate resistance after complete viral suppression in a patient with treatment-naïve chronic hepatitis B: A case report and review of the literature. World J Gastroenterol 2018; 24(17): 1919-1924 [PMID: 29740207 DOI: 10.3748/wjg.v24.i17.1919] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 11] [Article Influence: 4.7] [Reference Citation Analysis]
56 Abd El Aziz MA, Sacco R, Facciorusso A. Nucleos(t)ide analogues and Hepatitis B virus-related hepatocellular carcinoma: A literature review. Antivir Chem Chemother 2020;28:2040206620921331. [PMID: 32418480 DOI: 10.1177/2040206620921331] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
57 Lai MW, Liang KH, Lin WR, Huang YH, Huang SF, Chen TC, Yeh CT. Hepatocarcinogenesis in transgenic mice carrying hepatitis B virus pre-S/S gene with the sW172* mutation. Oncogenesis. 2016;5:e273. [PMID: 27918551 DOI: 10.1038/oncsis.2016.77.] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
58 Lun-Gen L. Antiviral Therapy of Liver Cirrhosis Related to Hepatitis B Virus Infection. J Clin Transl Hepatol 2014;2:197-201. [PMID: 26355652 DOI: 10.14218/JCTH.2014.00022] [Cited by in Crossref: 4] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
59 Qi X, Wang J, Chen L, Huang Y, Qin Y, Mao R, Zhang J. Impact of nucleos(t)ide analogue combination therapy on the estimated glomerular filtration rate in patients with chronic hepatitis B. Medicine94:e646. [PMID: 25881837 DOI: 10.1097/md.0000000000000646] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 2.2] [Reference Citation Analysis]
60 Wang YC, Yang SS, Su CW, Wang YJ, Lee KC, Huo TI, Lin HC, Huang YH. Predictors of response to pegylated interferon in chronic hepatitis B: a real-world hospital-based analysis. Sci Rep. 2016;6:29605. [PMID: 27405043 DOI: 10.1038/srep29605] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 5.6] [Reference Citation Analysis]
61 Chen Y, Gong J, Zhou W, Jie Y, Li Z, Chong Y, Hu B. A Novel Prediction Model for Significant Liver Fibrosis in Patients with Chronic Hepatitis B. Biomed Res Int 2020;2020:6839137. [PMID: 32695818 DOI: 10.1155/2020/6839137] [Reference Citation Analysis]
62 Sherman M. Predicting survival in hepatitis B. Gut. 2005;54:1521-1523. [PMID: 16227355 DOI: 10.1136/gut.2005.071332] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
63 Jun CH, Hong HJ, Chung MW, Park SY, Cho SB, Park CH, Joo YE, Kim HS, Choi SK, Rew JS. Risk factors for hepatocellular carcinoma in patients with drug-resistant chronic hepatitis B. World J Gastroenterol 2013; 19(40): 6834-6841 [PMID: 24187458 DOI: 10.3748/wjg.v19.i40.6834] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
64 Higashi-Kuwata N, Hayashi S, Das D, Kohgo S, Murakami S, Hattori SI, Imoto S, Venzon DJ, Singh K, Sarafianos SG, Tanaka Y, Mitsuya H. CMCdG, a Novel Nucleoside Analog with Favorable Safety Features, Exerts Potent Activity against Wild-Type and Entecavir-Resistant Hepatitis B Virus. Antimicrob Agents Chemother 2019;63:e02143-18. [PMID: 30670420 DOI: 10.1128/AAC.02143-18] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
65 Burns GS, Thompson AJ. Viral hepatitis B: clinical and epidemiological characteristics. Cold Spring Harb Perspect Med. 2014;4:a024935. [PMID: 25359547 DOI: 10.1101/cshperspect.a024935] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 4.7] [Reference Citation Analysis]
66 Yue-Meng W, Yang LH, Yang JH, Xu Y, Yang J, Song GB. The effect of plasma exchange on entecavir-treated chronic hepatitis B patients with hepatic de-compensation and acute-on-chronic liver failure. Hepatol Int. 2016;10:462-469. [PMID: 26482576 DOI: 10.1007/s12072-015-9667-4] [Cited by in Crossref: 34] [Cited by in F6Publishing: 27] [Article Influence: 5.7] [Reference Citation Analysis]
67 Imai K, Takai K, Miwa T, Maeda T, Hanai T, Shiraki M, Suetsugu A, Shimizu M. Increased Visceral Adipose Tissue and Hyperinsulinemia Raise the Risk for Recurrence of Non-B Non-C Hepatocellular Carcinoma after Curative Treatment. Cancers (Basel) 2021;13:1542. [PMID: 33810624 DOI: 10.3390/cancers13071542] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
68 Della Corte C, Aghemo A, Colombo M. Individualized hepatocellular carcinoma risk: The challenges for designing successful chemoprevention strategies. World J Gastroenterol 2013; 19(9): 1359-1371 [PMID: 23538741 DOI: 10.3748/wjg.v19.i9.1359] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
69 Liu T, Wang P, Cong M, Zhang D, Liu L, Li H, Zhai Q, Li Z, Jia J, You H. Matrix metalloproteinase-1 induction by diethyldithiocarbamate is regulated via Akt and ERK/miR222/ETS-1 pathways in hepatic stellate cells. Biosci Rep 2016;36:e00371. [PMID: 27412967 DOI: 10.1042/BSR20160111] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 2.2] [Reference Citation Analysis]
70 Hou FQ, Song LW, Yuan Q, Fang LL, Ge SX, Zhang J, Sheng JF, Xie DY, Shang J, Wu SH, Sun YT, Wei SF, Wang MR, Wan MB, Jia JD, Luo GH, Tang H, Li SC, Niu JQ, Zhou WD, Sun L, Xia NS, Wang GQ. Quantitative hepatitis B core antibody level is a new predictor for treatment response in HBeAg-positive chronic hepatitis B patients receiving peginterferon. Theranostics 2015;5:218-26. [PMID: 25553110 DOI: 10.7150/thno.10636] [Cited by in Crossref: 28] [Cited by in F6Publishing: 32] [Article Influence: 4.7] [Reference Citation Analysis]
71 Nagaoki Y, Hyogo H, Ando Y, Kosaka Y, Uchikawa S, Nishida Y, Teraoka Y, Morio K, Fujino H, Ono A, Nakahara T, Murakami E, Yamauchi M, Okamoto W, Kawaoka T, Tsuge M, Hiramatsu A, Miki D, Imamura M, Takahashi S, Chayama K, Aikata H. Increasing incidence of non-HBV- and non-HCV-related hepatocellular carcinoma: single-institution 20-year study. BMC Gastroenterol 2021;21:306. [PMID: 34332532 DOI: 10.1186/s12876-021-01884-5] [Reference Citation Analysis]
72 Tillmann HL. Antiviral therapy and resistance with hepatitis B virus infection. World J Gastroenterol 2007; 13(1): 125-140 [PMID: 17206760 DOI: 10.3748/wjg.v13.i1.125] [Cited by in CrossRef: 56] [Cited by in F6Publishing: 53] [Article Influence: 4.0] [Reference Citation Analysis]
73 Kim YJ, Sinn DH, Gwak GY, Choi MS, Koh KC, Paik SW, Yoo BC, Lee JH. Tenofovir rescue therapy for chronic hepatitis B patients after multiple treatment failures. World J Gastroenterol 2012; 18(47): 6996-7002 [PMID: 23322999 DOI: 10.3748/wjg.v18.i47.6996] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 21] [Article Influence: 2.0] [Reference Citation Analysis]
74 Casper C, Krantz EM, Corey L, Kuntz SR, Wang J, Selke S, Hamilton S, Huang ML, Wald A. Valganciclovir for suppression of human herpesvirus-8 replication: a randomized, double-blind, placebo-controlled, crossover trial. J Infect Dis 2008;198:23-30. [PMID: 18491970 DOI: 10.1086/588820] [Cited by in Crossref: 102] [Cited by in F6Publishing: 84] [Article Influence: 7.8] [Reference Citation Analysis]
75 Shinn BJ, Martin A, Coben RM, Conn MI, Prieto J, Kroop H, DiMarino AJ, Hann HW. Persistent risk for new, subsequent new and recurrent hepatocellular carcinoma despite successful anti-hepatitis B virus therapy and tumor ablation: The need for hepatitis B virus cure. World J Hepatol 2019; 11(1): 65-73 [PMID: 30705719 DOI: 10.4254/wjh.v11.i1.65] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
76 Chae HB, Hann HW. Baseline HBV DNA level is the most important factor associated with virologic breakthrough in chronic hepatitis B treated with lamivudine. World J Gastroenterol 2007; 13(30): 4085-4090 [PMID: 17696226 DOI: 10.3748/wjg.v13.i30.4085] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 16] [Article Influence: 0.9] [Reference Citation Analysis]
77 Zhang Z, Li J, Wang P, He T, Ouyang Y, Huang Y. Nomogram for cirrhosis in patients with chronic hepatitis B: A simple self-assessed scale for individual risk of cirrhosis. Sci Rep 2017;7:17493. [PMID: 29235488 DOI: 10.1038/s41598-017-17685-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
78 Xia Q, Shu Z, Ye T, Zhang M. Identification and Analysis of the Blood lncRNA Signature for Liver Cirrhosis and Hepatocellular Carcinoma. Front Genet 2020;11:595699. [PMID: 33365048 DOI: 10.3389/fgene.2020.595699] [Reference Citation Analysis]
79 Deng YR, Yoshida K, Jin QL, Murata M, Yamaguchi T, Tsuneyama K, Moritoki Y, Niu JQ, Matsuzaki K, Lian ZX. Reversible phospho-Smad3 signalling between tumour suppression and fibrocarcinogenesis in chronic hepatitis B infection. Clin Exp Immunol 2014;176:102-11. [PMID: 24372395 DOI: 10.1111/cei.12259] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
80 Lin YJ, Lee MH, Yang HI, Jen CL, You SL, Wang LY, Lu SN, Liu J, Chen CJ. Predictability of liver-related seromarkers for the risk of hepatocellular carcinoma in chronic hepatitis B patients. PLoS One. 2013;8:e61448. [PMID: 23613855 DOI: 10.1371/journal.pone.0061448] [Cited by in Crossref: 23] [Cited by in F6Publishing: 26] [Article Influence: 2.9] [Reference Citation Analysis]
81 Kim SU, Lee JH, Kim DY, Ahn SH, Jung KS, Choi EH, Park YN, Han KH, Chon CY, Park JY. Prediction of liver-related events using fibroscan in chronic hepatitis B patients showing advanced liver fibrosis. PLoS One. 2012;7:e36676. [PMID: 22574212 DOI: 10.1371/journal.pone.0036676] [Cited by in Crossref: 70] [Cited by in F6Publishing: 69] [Article Influence: 7.8] [Reference Citation Analysis]
82 Gupta N, Goyal M, Wu CH, Wu GY. The Molecular and Structural Basis of HBV-resistance to Nucleos(t)ide Analogs. J Clin Transl Hepatol. 2014;2:202-211. [PMID: 26357626 DOI: 10.14218/jcth.2014.00021] [Cited by in Crossref: 3] [Cited by in F6Publishing: 9] [Article Influence: 0.4] [Reference Citation Analysis]
83 Ozawa Y, Tamura T, Owada Y, Shimizu Y, Kemmochi A, Hisakura K, Matsuzaka T, Shimano H, Isoda H, Ohkohchi N. Evaluation of safety for hepatectomy in a novel mouse model with nonalcoholic-steatohepatitis. World J Gastroenterol 2018; 24(15): 1622-1631 [PMID: 29686469 DOI: 10.3748/wjg.v24.i15.1622] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
84 Wang X, Liu X, Dang Z, Yu L, Jiang Y, Wang X, Yan Z. Nucleos(t)ide Analogues for Reducing Hepatocellular Carcinoma in Chronic Hepatitis B Patients: A Systematic Review and Meta-Analysis. Gut Liver 2020;14:232-47. [PMID: 31158948 DOI: 10.5009/gnl18546] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 15.0] [Reference Citation Analysis]
85 Korean Association for the Study of the Liver. KASL Clinical Practice Guidelines: Management of chronic hepatitis B. Clin Mol Hepatol. 2012;18:109-162. [PMID: 22893865 DOI: 10.3350/cmh.2012.18.2.109] [Cited by in Crossref: 109] [Cited by in F6Publishing: 120] [Article Influence: 12.1] [Reference Citation Analysis]
86 Liang J, Liang X, Ma H, Nie L, Tian Y, Chen G, Wang Y. Detection of Hepatitis B Virus M204V Mutation Quantitatively via Real-time PCR. J Clin Transl Hepatol 2021;9:143-8. [PMID: 34007795 DOI: 10.14218/JCTH.2020.00118] [Reference Citation Analysis]
87 Rizzetto M. Treatment of hepatitis B virus cirrhosis. Hepat Mon 2012;12:309-11. [PMID: 22783340 DOI: 10.5812/hepatmon.6113] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
88 Ishikawa T. Clinical features of hepatitis B virus-related hepatocellular carcinoma. World J Gastroenterol 2010; 16(20): 2463-2467 [PMID: 20503445 DOI: 10.3748/wjg.v16.i20.2463] [Cited by in CrossRef: 24] [Cited by in F6Publishing: 22] [Article Influence: 2.2] [Reference Citation Analysis]
89 Villanueva A, Hernandez-Gea V, Llovet JM. Medical therapies for hepatocellular carcinoma: a critical view of the evidence. Nat Rev Gastroenterol Hepatol. 2013;10:34-42. [PMID: 23147664 DOI: 10.1038/nrgastro.2012.199] [Cited by in Crossref: 210] [Cited by in F6Publishing: 211] [Article Influence: 23.3] [Reference Citation Analysis]
90 Miyake Y, Kobashi H, Yamamoto K. Meta-analysis: the effect of interferon on development of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. J Gastroenterol 2009;44:470-5. [DOI: 10.1007/s00535-009-0024-z] [Cited by in Crossref: 42] [Cited by in F6Publishing: 35] [Article Influence: 3.5] [Reference Citation Analysis]
91 Schuppan D, Afdhal NH. Liver cirrhosis. Lancet. 2008;371:838-851. [PMID: 18328931 DOI: 10.1056/s0140-6736(08)60383-9] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
92 黄顺玲, 谭德明, 张涛, 彭忠田, 孙克伟, 刘菲, 傅荣泉, 郭光辉. 联合应用TGF-β、TGF-βR siRNA对小鼠急性肝损伤TGF-β/Smad信号传导通路相关基因表达的抑制. 世界华人消化杂志 2009; 17(24): 2444-2450 [DOI: 10.11569/wcjd.v17.i24.2444] [Reference Citation Analysis]
93 吴殿磊, 徐光华, 冯继红, 陈延平, 刘娜. 慢性HBV感染者复发期和免疫清除期在不同年龄阶段的临床病毒学特征. 世界华人消化杂志 2011; 19(15): 1639-1643 [DOI: 10.11569/wcjd.v19.i15.1639] [Reference Citation Analysis]
94 Wu X, Zhou J, Xie W, Ding H, Ou X, Chen G, Ma A, Xu X, Ma H, Xu Y, Liu X, Meng T, Wang L, Sun Y, Wang B, Kong Y, Ma H, You H, Jia J. Entecavir monotherapy versus de novo combination of lamivudine and adefovir for compensated hepatitis B virus-related cirrhosis: a real-world prospective multicenter cohort study. Infect Drug Resist 2019;12:745-57. [PMID: 31015765 DOI: 10.2147/IDR.S185120] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
95 Lin B, Pan CQ, Xie D, Xie J, Xie S, Zhang X, Wu B, Lin C, Gao Z. Entecavir improves the outcome of acute-on-chronic liver failure due to the acute exacerbation of chronic hepatitis B. Hepatol Int. 2013;7:460-467. [PMID: 26201778 DOI: 10.1007/s12072-012-9415-y] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
96 Sasaki R, Kanda T, Nakamura M, Nakamoto S, Haga Y, Wu S, Shirasawa H, Yokosuka O. Possible Involvement of Hepatitis B Virus Infection of Hepatocytes in the Attenuation of Apoptosis in Hepatic Stellate Cells. PLoS One 2016;11:e0146314. [PMID: 26731332 DOI: 10.1371/journal.pone.0146314] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.6] [Reference Citation Analysis]
97 Zoulim F, Durantel D. Antiviral therapies and prospects for a cure of chronic hepatitis B. Cold Spring Harb Perspect Med. 2015;5. [PMID: 25833942 DOI: 10.1101/cshperspect.a021501] [Cited by in Crossref: 92] [Cited by in F6Publishing: 91] [Article Influence: 15.3] [Reference Citation Analysis]
98 Singh L, Kruger HG, Maguire GEM, Govender T, Parboosing R. The role of nanotechnology in the treatment of viral infections. Ther Adv Infect Dis 2017;4:105-31. [PMID: 28748089 DOI: 10.1177/2049936117713593] [Cited by in Crossref: 78] [Cited by in F6Publishing: 86] [Article Influence: 19.5] [Reference Citation Analysis]
99 Jun BG, Kim YD, Cheon GJ, Kim ES, Jwa E, Kim SG, Kim YS, Kim BS, Jeong SW, Jang JY, Lee SH, Kim HS. Clinical significance of radiation-induced liver disease after stereotactic body radiation therapy for hepatocellular carcinoma. Korean J Intern Med 2018;33:1093-102. [PMID: 28844122 DOI: 10.3904/kjim.2016.412] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
100 Tziomalos K. Effect of antiviral treatment on the risk of hepatocellular carcinoma in patients with chronic hepatitis B. World J Hepatol 2010; 2(3): 91-93 [PMID: 21160979 DOI: 10.4254/wjh.v2.i3.91] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
101 Gidding HF, Dore GJ, Amin J, Law MG. Trends in all cause and viral liver disease-related hospitalizations in people with hepatitis B or C: a population-based linkage study. BMC Public Health 2011;11:52. [PMID: 21261993 DOI: 10.1186/1471-2458-11-52] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
102 Hsu CW, Chen YC, Chang ML, Lin CC, Lin SM, Chen WT, Chu YD, Yeh CT. Durability of Telbivudine-Associated Improvement of Renal Function Following Withdrawal or Switching of Antivirals in Chronic Hepatitis B Patients. Open Forum Infect Dis 2018;5:ofx271. [PMID: 29362723 DOI: 10.1093/ofid/ofx271] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
103 Liao WJ, Shi M, Chen JZ, Li AM. Local recurrence of hepatocellular carcinoma after radiofrequency ablation. World J Gastroenterol 2010; 16(40): 5135-5138 [PMID: 20976853 DOI: 10.3748/wjg.v16.i40.5135] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
104 Pallier C, Castéra L, Soulier A, Hézode C, Nordmann P, Dhumeaux D, Pawlotsky JM. Dynamics of hepatitis B virus resistance to lamivudine. J Virol. 2006;80:643-653. [PMID: 16378967 DOI: 10.1128/JVI.80.2.643-653.2006] [Cited by in Crossref: 71] [Cited by in F6Publishing: 32] [Article Influence: 4.7] [Reference Citation Analysis]
105 Zhang XQ, Zhang HY, You JP, Mao Q. Efficacy of pegylated interferon α2a in patients without HBeAg loss after the withdrawal of long-term lamivudine therapy. Virol J 2013;10:21. [PMID: 23320822 DOI: 10.1186/1743-422X-10-21] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
106 Ren FY, Piao DM, Piao XX. A one-year trial of entecavir treatment in patients with HBeAg-positive chronic hepatitis B. World J Gastroenterol 2007; 13(31): 4264-4267 [PMID: 17696259 DOI: 10.3748/wjg.v13.i31.4264] [Cited by in CrossRef: 26] [Cited by in F6Publishing: 25] [Article Influence: 1.9] [Reference Citation Analysis]
107 Burman BE, Mukhtar NA, Toy BC, Nguyen TT, Chen AH, Yu A, Berman P, Hammer H, Chan D, McCulloch CE, Khalili M. Hepatitis B management in vulnerable populations: gaps in disease monitoring and opportunities for improved care. Dig Dis Sci 2014;59:46-56. [PMID: 24052195 DOI: 10.1007/s10620-013-2870-z] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 3.3] [Reference Citation Analysis]
108 Kurihara T, Imazeki F, Yokosuka O, Fukai K, Kanda T, Kawai S, Saisho H. Effect of lamivudine in HBeAg-positive chronic hepatitis B: Discordant effect on HBeAg and HBV DNA according to pretreatment ALT level. World J Gastroenterol 2005; 11(22): 3346-3350 [PMID: 15948237 DOI: 10.3748/wjg.v11.i22.3346] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
109 Lee HJ, Eun R, Jang BI, Kim TN. Prevention by Lamivudine of hepatocellular carcinoma in patients infected with hepatitis B virus. Gut Liver. 2007;1:151-158. [PMID: 20485632 DOI: 10.5009/gnl.2007.1.2.151] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
110 Song DS, Kim W, Ahn SH, Yim HJ, Jang JY, Kweon YO, Cho YK, Kim YJ, Hong GY, Kim DJ, Jung YK, Sohn JH, Lee JW, Park SJ, Lee BS, Kim JH, Kim HS, Yoon SK, Kim MY, Lee KS, Lim YS, Lee WS, Yang JM, Kim KH, Han KH, Um SH. Continuing besifovir dipivoxil maleate versus switching from tenofovir disoproxil fumarate for treatment of chronic hepatitis B: Results of 192-week phase 3 trial. Clin Mol Hepatol 2021;27:346-59. [PMID: 33493393 DOI: 10.3350/cmh.2020.0307] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
111 Block TM, Gish R, Guo H, Mehta A, Cuconati A, Thomas London W, Guo JT. Chronic hepatitis B: what should be the goal for new therapies? Antiviral Res. 2013;98:27-34. [PMID: 23391846 DOI: 10.1016/j.antiviral.2013.01.006] [Cited by in Crossref: 82] [Cited by in F6Publishing: 74] [Article Influence: 10.3] [Reference Citation Analysis]
112 Ke Y, Ma L, You XM, Huang SX, Liang YR, Xiang BD, Li LQ, Zhong JH. Antiviral therapy for hepatitis B virus-related hepatocellular carcinoma after radical hepatectomy. Cancer Biol Med. 2013;10:158-164. [PMID: 24379991 DOI: 10.7497/j.issn.2095-3941.2013.03.006] [Cited by in F6Publishing: 23] [Reference Citation Analysis]
113 Schuppan D, Afdhal NH. Liver cirrhosis. Lancet. 2008;371:838-851. [PMID: 18328931 DOI: 10.1016/s0140-6736(08)60383-9] [Cited by in Crossref: 1212] [Cited by in F6Publishing: 533] [Article Influence: 93.2] [Reference Citation Analysis]
114 Tsai NC, Marcellin P, Buti M, Washington MK, Lee SS, Chan S, Trinh H, Flaherty JF, Kitrinos KM, Dinh P, Charuworn P, Subramanian GM, Gane E. Viral suppression and cirrhosis regression with tenofovir disoproxil fumarate in Asians with chronic hepatitis B. Dig Dis Sci. 2015;60:260-268. [PMID: 25179493 DOI: 10.1007/s10620-014-3336-7] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 2.6] [Reference Citation Analysis]
115 Dan YY, Wai CT, Lee YM, Sutedja DS, Seet BL, Lim SG. Outcome of lamivudine-resistant hepatitis B virus is generally benign except in cirrhotics. World J Gastroenterol 2005; 11(28): 4344-4350 [PMID: 16038032 DOI: 10.3748/wjg.v11.i28.4344] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
116 Yoshiji H, Nagoshi S, Akahane T, Asaoka Y, Ueno Y, Ogawa K, Kawaguchi T, Kurosaki M, Sakaida I, Shimizu M, Taniai M, Terai S, Nishikawa H, Hiasa Y, Hidaka H, Miwa H, Chayama K, Enomoto N, Shimosegawa T, Takehara T, Koike K. Evidence-based clinical practice guidelines for Liver Cirrhosis 2020. J Gastroenterol 2021;56:593-619. [PMID: 34231046 DOI: 10.1007/s00535-021-01788-x] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
117 Yang JD, Roberts LR. Epidemiology and management of hepatocellular carcinoma. Infect Dis Clin North Am 2010;24:899-919, viii. [PMID: 20937457 DOI: 10.1016/j.idc.2010.07.004] [Cited by in Crossref: 120] [Cited by in F6Publishing: 109] [Article Influence: 12.0] [Reference Citation Analysis]
118 Honda K, Seike M, Maehara SI, Tahara K, Anai H, Moriuchi A, Muro T. Lamivudine treatment enabling right hepatectomy for hepatocellular carcinoma in decompensated cirrhosis. World J Gastroenterol 2012; 18(20): 2586-2590 [PMID: 22654459 DOI: 10.3748/wjg.v18.i20.2586] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
119 Tag-Adeen M, Omar MZ, Abd-Elsalam FM, Hasaneen A, Mohamed MA, Elfeky HM, Said EM, Abdul-Aziz B, Osman AH, Ahmed ES, Osman GS, Abdul-Samie T. Assessment of liver fibrosis in Egyptian chronic hepatitis B patients: A comparative study including 5 noninvasive indexes. Medicine (Baltimore) 2018;97:e9781. [PMID: 29419671 DOI: 10.1097/MD.0000000000009781] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
120 Shinkai N, Nojima M, Iio E, Matsunami K, Toyoda H, Murakami S, Inoue T, Ogawa S, Kumada T, Tanaka Y. High levels of serum Mac-2-binding protein glycosylation isomer (M2BPGi) predict the development of hepatocellular carcinoma in hepatitis B patients treated with nucleot(s)ide analogues. J Gastroenterol 2018;53:883-9. [PMID: 29288305 DOI: 10.1007/s00535-017-1424-0] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 5.0] [Reference Citation Analysis]
121 Woo G, Tomlinson G, Yim C, Lilly L, Therapondos G, Wong DK, Ungar WJ, Einarson TR, Sherman M, Heathcote JE, Krahn M. Health state utilities and quality of life in patients with hepatitis B. Can J Gastroenterol 2012;26:445-51. [PMID: 22803020 DOI: 10.1155/2012/736452] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 3.7] [Reference Citation Analysis]
122 Wang Q, Yu CR. Association between liver targeted antiviral therapy in colorectal cancer and survival benefits: An appraisal. World J Clin Cases 2020; 8(11): 2111-2115 [PMID: 32548140 DOI: 10.12998/wjcc.v8.i11.2111] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
123 Yoo SH, Jang JW, Kwon JH, Jung SM, Jang B, Choi JY. Preemptive antiviral therapy with entecavir can reduce acute deterioration of hepatic function following transarterial chemoembolization. Clin Mol Hepatol 2016;22:458-65. [PMID: 28081589 DOI: 10.3350/cmh.2016.0054] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
124 Liaw YF, Leung N, Kao JH, Piratvisuth T, Gane E, Han KH, Guan R, Lau GK, Locarnini S; Chronic Hepatitis B Guideline Working Party of the Asian-Pacific Association for the Study of the Liver. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int. 2008;2:263-283. [PMID: 19669255 DOI: 10.1007/s12072-008-9080-3] [Cited by in Crossref: 636] [Cited by in F6Publishing: 660] [Article Influence: 48.9] [Reference Citation Analysis]
125 Liang TJ, Block TM, McMahon BJ, Ghany MG, Urban S, Guo JT, Locarnini S, Zoulim F, Chang KM, Lok AS. Present and future therapies of hepatitis B: From discovery to cure. Hepatology. 2015;62:1893-1908. [PMID: 26239691 DOI: 10.1002/hep.28025] [Cited by in Crossref: 193] [Cited by in F6Publishing: 182] [Article Influence: 32.2] [Reference Citation Analysis]
126 Goh GB, Li JW, Chang PE, Chow KY, Tan CK. Deciphering the epidemiology of hepatocellular carcinoma through the passage of time: A study of 1,401 patients across 3 decades. Hepatol Commun 2017;1:564-71. [PMID: 29404479 DOI: 10.1002/hep4.1059] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
127 Gai XD, Wu WF. Effect of entecavir in the treatment of patients with hepatitis B virus-related compensated and decompensated cirrhosis. Exp Ther Med 2017;14:3908-14. [PMID: 29043000 DOI: 10.3892/etm.2017.4963] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
128 Tong MJ, Hsien C, Song JJ, Kao JH, Sun HE, Hsu L, Han SH, Durazo FA, Saab S, Blatt LM. Factors associated with progression to hepatocellular carcinoma and to death from liver complications in patients with HBsAg-positive cirrhosis. Dig Dis Sci. 2009;54:1337-1346. [PMID: 19242792 DOI: 10.1007/s10620-009-0747-y] [Cited by in Crossref: 23] [Cited by in F6Publishing: 26] [Article Influence: 1.9] [Reference Citation Analysis]
129 Lee JI, Lee HW, Kim SU, Ahn SH, Lee KS. Follow-Up Liver Stiffness Measurements after Liver Resection Influence Oncologic Outcomes of Hepatitis-B-Associated Hepatocellular Carcinoma with Liver Cirrhosis. Cancers (Basel) 2019;11:E425. [PMID: 30934621 DOI: 10.3390/cancers11030425] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
130 Tateishi R, Okanoue T, Fujiwara N, Okita K, Kiyosawa K, Omata M, Kumada H, Hayashi N, Koike K. Clinical characteristics, treatment, and prognosis of non-B, non-C hepatocellular carcinoma: a large retrospective multicenter cohort study. J Gastroenterol. 2015;50:350-360. [PMID: 24929638 DOI: 10.1007/s00535-014-0973-8] [Cited by in Crossref: 97] [Cited by in F6Publishing: 85] [Article Influence: 13.9] [Reference Citation Analysis]
131 Chung SW, Chang Y, Lee HY, Cho EJ, Lee JH, Yu SJ, Yoon JH, Kim YJ. Is Combination Antiviral Therapy Mandatory for Maintenance Therapy in Fully Suppressed Multidrug-Resistant Hepatitis B Patients? Gastroenterol Res Pract 2018;2018:6948235. [PMID: 30647735 DOI: 10.1155/2018/6948235] [Reference Citation Analysis]
132 Gutierrez JA, Gish RG. Efficacy of combination treatment modalities for intermediate and advanced hepatocellular carcinoma: intra-arterial therapies, sorafenib and novel small molecules. Transl Cancer Res 2013;2:460-71. [PMID: 26504748 DOI: 10.3978/j.issn.2218-676X.2013.10.01] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
133 Kim S, Lee Y, Bang SM, Bak H, Yim SY, Lee YS, Yoo YJ, Jung YK, Kim JH, Seo YS, Yim HJ, Um SH, Byun KS, Yeon JE. Early Normalization of Alanine Aminotransferase during Antiviral Therapy Reduces Risk of Hepatocellular Carcinoma in HBV Patients. J Clin Med 2021;10:1840. [PMID: 33922708 DOI: 10.3390/jcm10091840] [Reference Citation Analysis]
134 Lee J, Yoo SH, Sohn W, Kim HW, Choi YS, Won JH, Heo JY, Park SJ, Park YM. Obesity and hepatocellular carcinoma in patients receiving entecavir for chronic hepatitis B. Clin Mol Hepatol 2016;22:339-49. [PMID: 27729627 DOI: 10.3350/cmh.2016.0021] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.2] [Reference Citation Analysis]
135 Kanwal F, Mapaskhi S, Smith D, Taddei T, Hussain K, Madu S, Duong N, White D, Cao Y, Mehta R, El-Serag H, Asch S, Midboe A. Implementation of a Population-Based Cirrhosis Identification and Management System. Clin Gastroenterol Hepatol 2018;16:1182-1186.e2. [PMID: 29803805 DOI: 10.1016/j.cgh.2018.01.041] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
136 Murata A, Amano N, Sato S, Tsuzura H, Tomishima K, Sato S, Matsumoto K, Shimada Y, Iijima K, Genda T. On-treatment Serum Mac-2 Binding Protein Glycosylation Isomer (M2BPGi) Level and Risk of Hepatocellular Carcinoma Development in Patients with Chronic Hepatitis B during Nucleot(s)ide Analogue Therapy. Int J Mol Sci 2020;21:E2051. [PMID: 32192084 DOI: 10.3390/ijms21062051] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
137 Jafri W, Kamran M. Hepatocellular Carcinoma in Asia: A Challenging Situation. Euroasian J Hepatogastroenterol 2019;9:27-33. [PMID: 31988864 DOI: 10.5005/jp-journals-10018-1292] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]
138 Sarin SK, Kumar M. Should chronic HBV infected patients with normal ALT treated: debate. Hepatol Int 2008;2:179-84. [PMID: 19669302 DOI: 10.1007/s12072-008-9065-2] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
139 Fernández-Rodríguez CM, Gutiérrez-García ML. Prevention of hepatocellular carcinoma in patients with chronic hepatitis B. World J Gastrointest Pharmacol Ther 2014; 5(3): 175-182 [PMID: 25133046 DOI: 10.4292/wjgpt.v5.i3.175] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 18] [Article Influence: 2.1] [Reference Citation Analysis]
140 Cai D, Pan C, Yu W, Dang S, Li J, Wu S, Jiang N, Wang M, Zhang Z, Lin F, Xin S, Yang Y, Shen B, Ren H. Comparison of the long-term efficacy of tenofovir and entecavir in nucleos(t)ide analogue-naïve HBeAg-positive patients with chronic hepatitis B: A large, multicentre, randomized controlled trials. Medicine (Baltimore) 2019;98:e13983. [PMID: 30608440 DOI: 10.1097/MD.0000000000013983] [Cited by in Crossref: 18] [Cited by in F6Publishing: 8] [Article Influence: 9.0] [Reference Citation Analysis]
141 Kim WR, Gores GJ. Recurrent hepatocellular carcinoma: it's the virus! J Clin Oncol 2013;31:3621-2. [PMID: 24002518 DOI: 10.1200/JCO.2013.51.8381] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
142 Ebrahimi H, Naderian M, Sohrabpour AA. New Concepts on Reversibility and Targeting of Liver Fibrosis; A Review Article. Middle East J Dig Dis. 2018;10:133-148. [PMID: 30186577 DOI: 10.15171/mejdd.2018.103] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
143 Kim WR, Terrault NA, Pedersen RA, Therneau TM, Edwards E, Hindman AA, Brosgart CL. Trends in waiting list registration for liver transplantation for viral hepatitis in the United States. Gastroenterology. 2009;137:1680-1686. [PMID: 19632234 DOI: 10.1053/j.gastro.2009.07.047] [Cited by in Crossref: 125] [Cited by in F6Publishing: 94] [Article Influence: 10.4] [Reference Citation Analysis]
144 Pan X, Chen J, Zhou L, Ou X, He F, Liu Y, Zheng S, Wang H, Cao B, Wang Z, Liu H, Liu G, Huang Z, Shen G, Liu S, Chen D. Efficacy and safety of continuous antiviral therapy from preconception to prevent perinatal transmission of hepatitis B virus. Sci Rep 2020;10:13631. [PMID: 32788743 DOI: 10.1038/s41598-020-70644-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
145 Yeh H, Chiang CC, Yen TH. Hepatocellular carcinoma in patients with renal dysfunction: Pathophysiology, prognosis, and treatment challenges. World J Gastroenterol 2021; 27(26): 4104-4142 [PMID: 34326614 DOI: 10.3748/wjg.v27.i26.4104] [Reference Citation Analysis]
146 Sinn DH, Lee JH, Kim K, Ahn JH, Kim JH, Lee DH, Yoon JH, Kang W, Gwak GY, Paik YH, Choi MS, Koh KC, Paik SW. A Novel Model for Predicting Hepatocellular Carcinoma Development in Patients with Chronic Hepatitis B and Normal Alanine Aminotransferase Levels. Gut Liver. 2017;11:528-534. [PMID: 27980231 DOI: 10.5009/gnl16403] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
147 Jiang L, Jiang LS, Cheng NS, Yan LN. Current prophylactic strategies against hepatitis B virus recurrence after liver transplantation. World J Gastroenterol 2009; 15(20): 2489-2499 [PMID: 19468999 DOI: 10.3748/wjg.15.2489] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.3] [Reference Citation Analysis]
148 Lim YS, Lee JY, Lee D, Shim JH, Lee HC, Lee YS, Suh DJ. Randomized trial of entecavir plus adefovir in patients with lamivudine-resistant chronic hepatitis B who show suboptimal response to lamivudine plus adefovir. Antimicrob Agents Chemother. 2012;56:2941-2947. [PMID: 22430972 DOI: 10.1128/aac.00338-12] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
149 de Almeida Pondé RA. Dynamic profile of the HBeAg-anti-HBe system in acute and chronic hepatitis B virus infection: A clinical-laboratory approach. Mol Biol Rep 2021;48:843-54. [PMID: 33296069 DOI: 10.1007/s11033-020-06056-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
150 Block TM, Rawat S, Brosgart CL. Chronic hepatitis B: A wave of new therapies on the horizon. Antiviral Res. 2015;121:69-81. [PMID: 26112647 DOI: 10.1016/j.antiviral.2015.06.014] [Cited by in Crossref: 50] [Cited by in F6Publishing: 44] [Article Influence: 8.3] [Reference Citation Analysis]
151 Nagao Y. The role of dentists in controlling hepatocellular carcinoma in Japan (Review). Exp Ther Med 2021;21:113. [PMID: 33335576 DOI: 10.3892/etm.2020.9545] [Reference Citation Analysis]
152 Jung KS, Park JY, Chon YE, Kim H, Kang W, Kim BK, Kim SU, Kim DY, Han K, Ahn SH. Clinical outcomes and predictors for relapse after cessation of oral antiviral treatment in chronic hepatitis B patients. J Gastroenterol 2016;51:830-9. [DOI: 10.1007/s00535-015-1153-1] [Cited by in Crossref: 50] [Cited by in F6Publishing: 52] [Article Influence: 8.3] [Reference Citation Analysis]
153 Lim YS, Lee JY, Lee D, Shim JH, Lee HC, Lee YS, Suh DJ. Randomized trial of the virologic response during up to two years of entecavir-adefovir combination therapy in multiple-drug-refractory chronic hepatitis B virus patients. Antimicrob Agents Chemother. 2013;57:3369-3374. [PMID: 23650172 DOI: 10.1128/aac.00587-13] [Cited by in Crossref: 9] [Cited by in F6Publishing: 1] [Article Influence: 1.1] [Reference Citation Analysis]
154 Park JY, Heo J, Lee TJ, Yim HJ, Yeon JE, Lim YS, Seo MJ, Ahn SH, Lee MS. A novel estimation of the relative economic value in terms of different chronic hepatitis B treatment options. PLoS One 2013;8:e57900. [PMID: 23536775 DOI: 10.1371/journal.pone.0057900] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
155 Kim YW, Kwon JH, Chung E, Lee SW, Lee JY, Jang JW, Chung KW, Nam SW. Short Term Virologic Efficacies of Telbivudine versus Entecavir against Hepatitis B-Related Hepatocellular Carcinoma. Gastroenterol Res Pract 2015;2015:181065. [PMID: 25878659 DOI: 10.1155/2015/181065] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
156 Kusumoto S, Tanaka Y, Mizokami M, Ueda R. Reactivation of hepatitis B virus following systemic chemotherapy for malignant lymphoma. Int J Hematol. 2009;90:13-23. [PMID: 19544079 DOI: 10.1007/s12185-009-0359-5] [Cited by in Crossref: 122] [Cited by in F6Publishing: 107] [Article Influence: 10.2] [Reference Citation Analysis]
157 Chainuvati S, Cheng J, Hou JL, Hsu CW, Jia JD, Komolmit P, Kwon SY, Lee CH, Li H, Li Y. Patterns of managing chronic hepatitis B treatment-related drug resistance: a survey of physicians in Mainland China, South Korea, Taiwan, and Thailand. Hepatol Int. 2009;3:453-460. [PMID: 19669246 DOI: 10.1007/s12072-009-9139-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
158 Fukui H, Saito H, Ueno Y, Uto H, Obara K, Sakaida I, Shibuya A, Seike M, Nagoshi S, Segawa M, Tsubouchi H, Moriwaki H, Kato A, Hashimoto E, Michitaka K, Murawaki T, Sugano K, Watanabe M, Shimosegawa T. Evidence-based clinical practice guidelines for liver cirrhosis 2015. J Gastroenterol 2016;51:629-50. [PMID: 27246107 DOI: 10.1007/s00535-016-1216-y] [Cited by in Crossref: 181] [Cited by in F6Publishing: 162] [Article Influence: 36.2] [Reference Citation Analysis]
159 Heidrich B, Manns MP, Wedemeyer H. Treatment options for hepatitis delta virus infection. Curr Infect Dis Rep. 2013;15:31-38. [PMID: 23242761 DOI: 10.1007/s11908-012-0307-z] [Cited by in Crossref: 47] [Cited by in F6Publishing: 43] [Article Influence: 5.9] [Reference Citation Analysis]
160 Liang KH, Ahn SH, Lee HW, Huang YH, Chien RN, Hu TH, Lin KH, Yeh CS, Hsu CW, Lin CL, Pan TL, Ke PY, Chang ML, Yeh CT. A novel risk score for hepatocellular carcinoma in Asian cirrhotic patients: a multicentre prospective cohort study. Sci Rep 2018;8:8608. [PMID: 29872158 DOI: 10.1038/s41598-018-26992-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
161 Wong GLH, Wong VWS. Risk prediction of hepatitis B virus-related hepatocellular carcinoma in the era of antiviral therapy. World J Gastroenterol 2013; 19(39): 6515-6522 [PMID: 24151375 DOI: 10.3748/wjg.v19.i39.6515] [Cited by in CrossRef: 30] [Cited by in F6Publishing: 26] [Article Influence: 3.8] [Reference Citation Analysis]
162 Lodato F, Mazzella G, Festi D, Azzaroli F, Colecchia A, Roda E. Hepatocellular carcinoma prevention: A worldwide emergence between the opulence of developed countries and the economic constraints of developing nations. World J Gastroenterol 2006; 12(45): 7239-7249 [PMID: 17143937 DOI: 10.3748/wjg.v12.i45.7239] [Cited by in CrossRef: 59] [Cited by in F6Publishing: 52] [Article Influence: 3.9] [Reference Citation Analysis]
163 Shindo M, Chayama K, Mochida S, Toyota J, Tomita E, Kumada H, Yokosuka O, Sata M, Hayashi N, Suzuki K, Okanoue T, Tsubouchi H, Ishikawa H, Seriu T, Omata M. Antiviral activity, dose-response relationship, and safety of entecavir following 24-week oral dosing in nucleoside-naive Japanese adult patients with chronic hepatitis B: a randomized, double-blind, phase II clinical trial. Hepatol Int 2009;3:445-52. [PMID: 19669249 DOI: 10.1007/s12072-009-9135-0] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
164 Toy M, Wei B, Virdi TS, Le A, Trinh H, Li J, Zhang J, Hsing AW, So SK, Nguyen MH. Racial/ethnic- and county-specific prevalence of chronic hepatitis B and its burden in California. Hepatol Med Policy 2018;3:6. [PMID: 30288329 DOI: 10.1186/s41124-018-0034-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
165 Fung J, Lai CL, Yuen MF. Management of chronic hepatitis B in severe liver disease. World J Gastroenterol 2014; 20(43): 16053-16061 [PMID: 25473157 DOI: 10.3748/wjg.v20.i43.16053] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
166 El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology. 2012;142:1264-1273.e1. [PMID: 22537432 DOI: 10.1053/j-gastro.2011.12.061] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
167 Wang X, Liu X, Dang Z, Yu L, Jiang Y, Wang X, Yang Z. Nucleos(t)ide Analogues for Reducing Hepatocellular Carcinoma in Chronic Hepatitis B Patients: A Systematic Review and Meta-Analysis. Gut Liver. 2019;. [PMID: 31158948 DOI: 10.5009/gnl18546.] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
168 Desalegn H, Aberra H, Berhe N, Mekasha B, Stene-Johansen K, Krarup H, Pereira AP, Gundersen SG, Johannessen A. Treatment of chronic hepatitis B in sub-Saharan Africa: 1-year results of a pilot program in Ethiopia. BMC Med 2018;16:234. [PMID: 30554571 DOI: 10.1186/s12916-018-1229-x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
169 Jeon JW, Shin HP, Lee JI, Joo KR, Cha JM, Park JJ, Lim JU, Lim K, Kim S. Efficacy of entecavir and adefovir combination therapy for patients with lamivudine- and entecavir-resistant chronic hepatitis B. Dig Dis Sci. 2012;57:1358-1365. [PMID: 22134785 DOI: 10.1007/s10620-011-1988-0] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
170 Llovet JM, Lok A. Hepatitis B virus genotype and mutants: risk factors for hepatocellular carcinoma. J Natl Cancer Inst 2008;100:1121-3. [PMID: 18695130 DOI: 10.1093/jnci/djn261] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.0] [Reference Citation Analysis]
171 Ke Y, Wang L, Li LQ, Zhong JH. Nucleos(t)ide analogues to treat hepatitis B virus-related hepatocellular carcinoma after radical resection. World J Hepatol 2014; 6(9): 652-659 [PMID: 25276281 DOI: 10.4254/wjh.v6.i9.652] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
172 Tillmann HL. The treatment of chronic hepatitis B: Focus on adefovir-like antivirals. Ther Clin Risk Manag 2008;4:797-802. [PMID: 19209262 DOI: 10.2147/tcrm.s1965] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
173 Daha TJ, Bilkert-Mooiman MA, Ballemans C, Frijstein G, Keeman JN, de Man RA, van Steenbergen JE, Weers-Pothoff G, Zaaijer HL. Hepatitis B virus infected health care workers in The Netherlands, 2000-2008. Eur J Clin Microbiol Infect Dis 2009;28:1041-4. [PMID: 19350292 DOI: 10.1007/s10096-009-0744-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
174 Niederau C. Chronic hepatitis B in 2014: Great therapeutic progress, large diagnostic deficit. World J Gastroenterol 2014; 20(33): 11595-11617 [PMID: 25206267 DOI: 10.3748/wjg.v20.i33.11595] [Cited by in CrossRef: 31] [Cited by in F6Publishing: 32] [Article Influence: 4.4] [Reference Citation Analysis]
175 El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology. 2012;142:1264-1273.e1. [PMID: 22537432 DOI: 10.1053/j.gastro.2011.12.061}] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
176 Kao JH, Jeng WJ, Ning Q, Su TH, Tseng TC, Ueno Y, Yuen MF. APASL guidance on stopping nucleos(t)ide analogues in chronic hepatitis B patients. Hepatol Int 2021;15:833-51. [PMID: 34297329 DOI: 10.1007/s12072-021-10223-5] [Reference Citation Analysis]
177 Yang DH, Wang WP, Zhang Q, Pan HY, Huang YC, Zhang JJ. Hepatocellular carcinoma progression in hepatitis B virus-related cirrhosis patients receiving nucleoside (acid) analogs therapy: A retrospective cross-sectional study. World J Gastroenterol 2021; 27(17): 2025-2038 [PMID: 34007137 DOI: 10.3748/wjg.v27.i17.2025] [Reference Citation Analysis]
178 Tawada A, Kanda T, Yokosuka O. Current and future directions for treating hepatitis B virus infection. World J Hepatol 2015; 7(11): 1541-1552 [PMID: 26085913 DOI: 10.4254/wjh.v7.i11.1541] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 3.3] [Reference Citation Analysis]
179 Marzio DHD, Hann HW. Then and now: The progress in hepatitis B treatment over the past 20 years. World J Gastroenterol 2014; 20(2): 401-413 [PMID: 24574709 DOI: 10.3748/wjg.v20.i2.401] [Cited by in CrossRef: 32] [Cited by in F6Publishing: 27] [Article Influence: 4.6] [Reference Citation Analysis]
180 Duseja A. Reversibility of hepatic fibrosis and cirrhosis-another evidence. J Clin Exp Hepatol. 2013;3:167-168. [PMID: 25755493 DOI: 10.1016/j.jceh.2013.05.007] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
181 Chuma M, Hige S, Kamiyama T, Meguro T, Nagasaka A, Nakanishi K, Yamamoto Y, Nakanishi M, Kohara T, Sho T, Yamamoto K, Horimoto H, Kobayashi T, Yokoo H, Matsushita M, Todo S, Asaka M. The influence of hepatitis B DNA level and antiviral therapy on recurrence after initial curative treatment in patients with hepatocellular carcinoma. J Gastroenterol. 2009;44:991-999. [PMID: 19554391 DOI: 10.1007/s00535-009-0093-z] [Cited by in Crossref: 75] [Cited by in F6Publishing: 77] [Article Influence: 6.3] [Reference Citation Analysis]
182 Jiang Y, Ma Z, Xin G, Yan H, Li W, Xu H, Hao C, Niu J, Zhao P. Th1 and Th2 immune response in chronic hepatitis B patients during a long-term treatment with adefovir dipivoxil. Mediators Inflamm. 2010;2010:143026. [PMID: 21127728 DOI: 10.1155/2010/143026] [Cited by in Crossref: 34] [Cited by in F6Publishing: 43] [Article Influence: 3.1] [Reference Citation Analysis]
183 Xu X, Su Y, Song R, Sheng Y, Ai W, Wu X, Liu H. Performance of transient elastography assessing fibrosis of single hepatitis B virus infection: a systematic review and meta-analysis of a diagnostic test. Hepatol Int. 2015;9:558-566. [PMID: 26187292 DOI: 10.1007/s12072-015-9643-z] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 3.2] [Reference Citation Analysis]
184 Shen Y, Jia Y, Zhou J, Ji J, Xun P. Bayesian Network Meta-Analysis for Assessing Adverse Effects of Anti-hepatitis B Drugs. Clin Drug Investig 2019;39:835-46. [PMID: 31228017 DOI: 10.1007/s40261-019-00802-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
185 Zhu Q, Li N, Zeng X, Han Q, Li F, Yang C, Lv Y, Zhou Z, Liu Z. Hepatocellular carcinoma in a large medical center of China over a 10-year period: evolving therapeutic option and improving survival. Oncotarget. 2015;6:4440-4450. [PMID: 25686836 DOI: 10.18632/oncotarget.2913] [Cited by in Crossref: 38] [Cited by in F6Publishing: 45] [Article Influence: 6.3] [Reference Citation Analysis]
186 Rockey DC. Translating an understanding of the pathogenesis of hepatic fibrosis to novel therapies. Clin Gastroenterol Hepatol. 2013;11:224-31.e1-5. [PMID: 23305825 DOI: 10.1016/j.cgh.2013.01.005] [Cited by in Crossref: 57] [Cited by in F6Publishing: 48] [Article Influence: 7.1] [Reference Citation Analysis]
187 Wang H, Shang X, Wan X, Xiang X, Mao Q, Deng G, Wu Y. Increased hepatocellular carcinoma risk in chronic hepatitis B patients with persistently elevated serum total bile acid: a retrospective cohort study. Sci Rep 2016;6:38180. [PMID: 27905528 DOI: 10.1038/srep38180] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
188 Lok AS. Progress in hepatitis B: a 30-year journey through three continents. Hepatology 2014;60:4-11. [PMID: 24619499 DOI: 10.1002/hep.27120] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
189 Hann HW, Chae HB, Dunn SR. Tenofovir (TDF) has stronger antiviral effect than adefovir (ADV) against lamivudine (LAM)-resistant hepatitis B virus (HBV). Hepatol Int. 2008;2:244-249. [PMID: 19669311 DOI: 10.1007/s12072-008-9045-6] [Cited by in Crossref: 25] [Cited by in F6Publishing: 31] [Article Influence: 1.9] [Reference Citation Analysis]
190 Mehta N, Sarkar M, Dodge JL, Fidelman N, Roberts JP, Yao FY. Intention to treat outcome of T1 hepatocellular carcinoma with the "wait and not ablate" approach until meeting T2 criteria for liver transplant listing. Liver Transpl 2016;22:178-87. [PMID: 26479422 DOI: 10.1002/lt.24360] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 6.4] [Reference Citation Analysis]
191 Lian JS, Zeng LY, Chen JY, Jia HY, Zhang YM, Xiang DR, Yu L, Hu JH, Lu YF, Zheng L, Li LJ, Yang YD. De novo combined lamivudine and adefovir dipivoxil therapy vs entecavir monotherapy for hepatitis B virus-related decompensated cirrhosis. World J Gastroenterol 2013; 19(37): 6278-6283 [PMID: 24115827 DOI: 10.3748/wjg.v19.i37.6278] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
192 Marcellin P, Zoulim F, Hézode C, Causse X, Roche B, Truchi R, Pauwels A, Ouzan D, Dumortier J, Pageaux GP, Bourlière M, Riachi G, Zarski JP, Cadranel JF, Tilliet V, Stern C, Pétour P, Libert O, Consoli SM, Larrey D. Effectiveness and Safety of Tenofovir Disoproxil Fumarate in Chronic Hepatitis B: A 3-Year, Prospective, Real-World Study in France. Dig Dis Sci 2016;61:3072-83. [PMID: 26821154 DOI: 10.1007/s10620-015-4027-8] [Cited by in Crossref: 43] [Cited by in F6Publishing: 42] [Article Influence: 8.6] [Reference Citation Analysis]
193 Zhou R, Zhou YP, Lin C, Gao HB, Huang SW, Huang ZX, Sun F, Lin Y, Zhang DQ, Lin QF, Ao W, Pan C. Baseline prognostic factors and statistic model to predict early virological response in telbivudine-treated patients with chronic hepatitis B. Hepat Mon 2013;13:e15573. [PMID: 24403918 DOI: 10.5812/hepatmon.15573] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
194 Hsu CW, Liang KH, Huang SF, Tsao KC, Yeh CT. Development of a non-invasive fibrosis test for chronic hepatitis B patients and comparison with other unpatented scores. BMC Res Notes 2013;6:212. [PMID: 23706143 DOI: 10.1186/1756-0500-6-212] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
195 Liaw YF, Omata M, Sarin SK. Responding to the progress in hepatology: beyond the boundaries. Hepatol Int 2007;1:1-2. [PMID: 19669345 DOI: 10.1007/s12072-007-5002-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
196 Post SE, Sodhi NK, Peng CH, Wan K, Pollack HJ. A simulation shows that early treatment of chronic hepatitis B infection can cut deaths and be cost-effective. Health Aff (Millwood) 2011;30:340-8. [PMID: 21289356 DOI: 10.1377/hlthaff.2008.0905] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 2.0] [Reference Citation Analysis]
197 Son SH, Jang HS, Jo IY, Choi BO, Jang JW, Yoon SK, Kay CS. Significance of an increase in the Child-Pugh score after radiotherapy in patients with unresectable hepatocellular carcinoma. Radiat Oncol 2014;9:101. [PMID: 24779518 DOI: 10.1186/1748-717X-9-101] [Cited by in Crossref: 16] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
198 Joshita S, Ota M, Kobayashi H, Wakabayashi SI, Yamashita Y, Sugiura A, Yamazaki T, Tanaka E, Umemura T. Association analysis of KIR/HLA genotype with liver cirrhosis, hepatocellular carcinoma, and NUC freedom in chronic hepatitis B patients. Sci Rep 2021;11:21424. [PMID: 34728722 DOI: 10.1038/s41598-021-01014-x] [Reference Citation Analysis]
199 Varbobitis I, Papatheodoridis GV. The assessment of hepatocellular carcinoma risk in patients with chronic hepatitis B under antiviral therapy. Clin Mol Hepatol. 2016;22:319-326. [PMID: 27729632 DOI: 10.3350/cmh.2016.0045] [Cited by in Crossref: 47] [Cited by in F6Publishing: 45] [Article Influence: 9.4] [Reference Citation Analysis]
200 Song BC. Switch to tenofovir-based therapy or to continue adefovir-based therapy in CHB patients with suboptimal response to adefovir-based combination? Clin Mol Hepatol 2016;22:439-42. [PMID: 28081595 DOI: 10.3350/cmh.2016.0108] [Reference Citation Analysis]
201 Ding R, Lu W, Zhou X, Huang D, Wang Y, Li X, Yan L, Lin W, Song S, Zhang Z, Chen L. A Novel Non-invasive Model Based on GPR for the Prediction of Liver Fibrosis in Patients With Chronic Hepatitis B. Front Med (Lausanne) 2021;8:727706. [PMID: 34631748 DOI: 10.3389/fmed.2021.727706] [Reference Citation Analysis]
202 Lam YF, Yuen MF, Seto WK, Lai CL. Current Antiviral Therapy of Chronic Hepatitis B: Efficacy and Safety. Curr Hepat Rep. 2011;10:235-243. [PMID: 22131901 DOI: 10.1007/s11901-011-0109-z] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 1.8] [Reference Citation Analysis]
203 Iida-Ueno A, Enomoto M, Tamori A, Kawada N. Hepatitis B virus infection and alcohol consumption. World J Gastroenterol 2017; 23(15): 2651-2659 [PMID: 28487602 DOI: 10.3748/wjg.v23.i15.2651] [Cited by in CrossRef: 30] [Cited by in F6Publishing: 27] [Article Influence: 7.5] [Reference Citation Analysis]
204 Vlachogiannakos J, Papatheodoridis G. Hepatocellular carcinoma in chronic hepatitis B patients under antiviral therapy. World J Gastroenterol 2013; 19(47): 8822-8830 [PMID: 24379605 DOI: 10.3748/wjg.v19.i47.8822] [Cited by in CrossRef: 29] [Cited by in F6Publishing: 28] [Article Influence: 3.6] [Reference Citation Analysis]
205 Watanabe T, Tokumoto Y, Joko K, Michitaka K, Mashiba T, Hiraoka A, Ochi H, Koizumi Y, Tada F, Hirooka M, Yoshida O, Imai Y, Abe M, Hiasa Y. Effects of long-term entecavir treatment on the incidence of hepatocellular carcinoma in chronic hepatitis B patients. Hepatol Int. 2016;10:320-327. [PMID: 26198757 DOI: 10.1007/s12072-015-9647-8] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
206 Liang P, Huang C, Liang SX, Li YF, Huang SX, Lian ZP, Liu JM, Tang Y, Lu HJ. Effect of CyberKnife stereotactic body radiation therapy for hepatocellular carcinoma on hepatic toxicity. Onco Targets Ther 2016;9:7169-75. [PMID: 27920555 DOI: 10.2147/OTT.S112290] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
207 Kim SB, Song IH, Kim YM, Noh R, Kang HY, Lee HI, Yang HY, Kim AN, Chae HB, Lee SH, Kim HS, Lee TH, Kang YW, Lee ES, Kim SH, Lee BS, Lee HY. Long-term treatment outcomes of clevudine in antiviral-naive patients with chronic hepatitis B. World J Gastroenterol 2012; 18(47): 6943-6950 [PMID: 23322992 DOI: 10.3748/wjg.v18.i47.6943] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
208 Lv GC, Yao JM, Yang YD, Zheng L, Sheng JF, Chen Y, Li LJ. Efficacy of combined therapy in patients with hepatitis B virus-related decompensated cirrhosis. World J Gastroenterol 2013; 19(22): 3481-3486 [PMID: 23801842 DOI: 10.3748/wjg.v19.i22.3481] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
209 Selicean S, Wang C, Guixé-Muntet S, Stefanescu H, Kawada N, Gracia-Sancho J. Regression of portal hypertension: underlying mechanisms and therapeutic strategies. Hepatol Int 2021;15:36-50. [PMID: 33544313 DOI: 10.1007/s12072-021-10135-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
210 Dan YY, Aung MO, Lim SG. The economics of treating chronic hepatitis B in Asia. Hepatol Int 2008;2:284-95. [PMID: 19669256 DOI: 10.1007/s12072-008-9049-2] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 1.8] [Reference Citation Analysis]
211 Toy M, Hutton DW, So SK. Cost-Effectiveness and Cost Thresholds of Generic and Brand Drugs in a National Chronic Hepatitis B Treatment Program in China. PLoS One 2015;10:e0139876. [PMID: 26536626 DOI: 10.1371/journal.pone.0139876] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
212 Al-Mahtab M, Akbar SM, Aguilar JC, Uddin MH, Khan MS, Rahman S. Therapeutic potential of a combined hepatitis B virus surface and core antigen vaccine in patients with chronic hepatitis B. Hepatol Int 2013;7:981-9. [PMID: 26202028 DOI: 10.1007/s12072-013-9486-4] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 3.6] [Reference Citation Analysis]
213 Sherman M, Lee SS. Canadian patients with chronic hepatitis B cannot access appropriate drug treatments: a call for change. Can J Gastroenterol 2011;25:538-41. [PMID: 22059156 DOI: 10.1155/2011/864046] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
214 Kwon SY, Park YK, Ahn SH, Cho ES, Choe WH, Lee CH, Kim BK, Ko SY, Choi HS, Park ES. Identification and characterization of clevudine-resistant mutants of hepatitis B virus isolated from chronic hepatitis B patients. J Virol. 2010;84:4494-4503. [PMID: 20164224 DOI: 10.1128/jvi.02066-09] [Cited by in Crossref: 31] [Cited by in F6Publishing: 23] [Article Influence: 2.8] [Reference Citation Analysis]
215 Fujiwara N, Friedman SL, Goossens N, Hoshida Y. Risk factors and prevention of hepatocellular carcinoma in the era of precision medicine. J Hepatol 2018;68:526-49. [PMID: 28989095 DOI: 10.1016/j.jhep.2017.09.016] [Cited by in Crossref: 198] [Cited by in F6Publishing: 198] [Article Influence: 49.5] [Reference Citation Analysis]
216 Kim KM, Choi WB, Lim YS, Lee HC, Chung YH, Lee YS, Suh DJ. Adefovir dipivoxil alone or in combination with ongoing lamivudine in patients with decompensated liver disease and lamivudine-resistant hepatitis B virus. J Korean Med Sci. 2005;20:821-828. [PMID: 16224157 DOI: 10.3346/jkms.2005.20.5.821] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.1] [Reference Citation Analysis]
217 Chang BW, Kaung A, Robbins L, Tran TT. Hepatitis B: Working Towards a Cure. Curr Gastroenterol Rep 2015;17:35. [PMID: 26275560 DOI: 10.1007/s11894-015-0460-2] [Reference Citation Analysis]
218 Yang J, Sun H, Liu Q. The Comparative Efficacy and Safety of Entecavir and Lamivudine in Patients with HBV-Associated Acute-on-Chronic Liver Failure: A Systematic Review and Meta-Analysis. Gastroenterol Res Pract. 2016;2016:5802674. [PMID: 27148364 DOI: 10.1155/2016/5802674] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
219 Abdel-Hady M, Kelly D. Chronic hepatitis B in children and adolescents: epidemiology and management. Paediatr Drugs 2013;15:311-7. [PMID: 23529864 DOI: 10.1007/s40272-013-0010-z] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
220 Ramírez-Mena A, Glass TR, Winter A, Kimera N, Ntamatungiro A, Hatz C, Tanner M, Battegay M, Furrer H, Wandeler G, Letang E. Prevalence and Outcomes of Hepatitis B Coinfection and Associated Liver Disease Among Antiretroviral Therapy-Naive Individuals in a Rural Tanzanian Human Immunodeficiency Virus Cohort. Open Forum Infect Dis 2016;3:ofw162. [PMID: 27704017 DOI: 10.1093/ofid/ofw162] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 2.6] [Reference Citation Analysis]
221 Buti M, Fung S, Gane E, Afdhal NH, Flisiak R, Gurel S, Flaherty JF, Martins EB, Yee LJ, Dinh P, Bornstein JD, Mani Subramanian G, Janssen HL, George J, Marcellin P. Long-term clinical outcomes in cirrhotic chronic hepatitis B patients treated with tenofovir disoproxil fumarate for up to 5 years. Hepatol Int. 2015;9:243-250. [PMID: 25788199 DOI: 10.1007/s12072-015-9614-4] [Cited by in Crossref: 40] [Cited by in F6Publishing: 36] [Article Influence: 6.7] [Reference Citation Analysis]
222 Hige S, Yamamoto Y, Yoshida S, Kobayashi T, Horimoto H, Yamamoto K, Sho T, Natsuizaka M, Nakanishi M, Chuma M, Asaka M. Sensitive assay for quantification of hepatitis B virus mutants by use of a minor groove binder probe and peptide nucleic acids. J Clin Microbiol 2010;48:4487-94. [PMID: 20926703 DOI: 10.1128/JCM.00731-10] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
223 Leung N. Recent data on treatment of chronic hepatitis B with nucleos(t)ide analogues. Hepatol Int 2008;2:163-78. [PMID: 19669301 DOI: 10.1007/s12072-008-9061-6] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 2.1] [Reference Citation Analysis]
224 Tana MM, Ghany MG. Hepatitis B virus treatment: Management of antiviral drug resistance. Clin Liver Dis (Hoboken) 2013;2:24-8. [PMID: 30992816 DOI: 10.1002/cld.162] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
225 Lacey LF, Gane E. The cost-effectiveness of long-term antiviral therapy in the management of HBeAg-positive and HBeAg-negative chronic hepatitis B in Singapore. J Viral Hepat 2007;14:751-66. [PMID: 17927611 DOI: 10.1111/j.1365-2893.2007.00865.x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]
226 Tsai TY, Livneh H, Hung TH, Lin IH, Lu MC, Yeh CC. Associations between prescribed Chinese herbal medicine and risk of hepatocellular carcinoma in patients with chronic hepatitis B: a nationwide population-based cohort study. BMJ Open. 2017;7:e014571. [PMID: 28122837 DOI: 10.1136/bmjopen-2016-014571] [Cited by in Crossref: 37] [Cited by in F6Publishing: 32] [Article Influence: 9.3] [Reference Citation Analysis]
227 Cherqui D, Laurent A, Tayar C, Chang S, Van Nhieu JT, Loriau J, Karoui M, Duvoux C, Dhumeaux D, Fagniez PL. Laparoscopic liver resection for peripheral hepatocellular carcinoma in patients with chronic liver disease: midterm results and perspectives. Ann Surg 2006;243:499-506. [PMID: 16552201 DOI: 10.1097/01.sla.0000206017.29651.99] [Cited by in Crossref: 229] [Cited by in F6Publishing: 211] [Article Influence: 15.3] [Reference Citation Analysis]
228 Chan HL. Antiviral therapy for acute-on-chronic liver failure in chronic hepatitis B: is it too late? Dig Dis Sci 2010;55:2126-8. [PMID: 20458619 DOI: 10.1007/s10620-010-1266-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
229 Zeng Z, Guan L, An P, Sun S, O’Brien SJ, Winkler CA. A population-based study to investigate host genetic factors associated with hepatitis B infection and pathogenesis in the Chinese population. BMC Infect Dis. 2008;8:1. [PMID: 18171470 DOI: 10.1186/1471-2334-8-1] [Cited by in Crossref: 47] [Cited by in F6Publishing: 33] [Article Influence: 3.6] [Reference Citation Analysis]
230 Zhang W, Wang X, Wang Y, Zhao X, Duan W, Wang Q, Wu X, Kong Y, Ma H, You H, Ou X, Jia J. Effective viral suppression is necessary to reduce hepatocellular carcinoma development in cirrhotic patients with chronic hepatitis B: Results of a 10-year follow up. Medicine (Baltimore) 2017;96:e8454. [PMID: 29095292 DOI: 10.1097/MD.0000000000008454] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
231 Ashtari S, Pourhoseingholi MA, Sharifian A, Zali MR. Hepatocellular carcinoma in Asia: Prevention strategy and planning. World J Hepatol 2015; 7(12): 1708-1717 [PMID: 26140091 DOI: 10.4254/wjh.v7.i12.1708] [Cited by in Crossref: 54] [Cited by in F6Publishing: 45] [Article Influence: 9.0] [Reference Citation Analysis]
232 Chen CH, Chiu YC, Lu SN, Lee CM, Wang JH, Hu TH, Hung CH. Serum hepatitis B surface antigen levels predict treatment response to nucleos(t)ide analogues. World J Gastroenterol 2014; 20(24): 7686-7695 [PMID: 24976706 DOI: 10.3748/wjg.v20.i24.7686] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
233 Masaki K, Suzuki F, Hara T, Kawamura Y, Sezaki H, Hosaka T, Akuta N, Kobayashi M, Saitoh S, Suzuki Y, Arase Y, Ikeda K, Kobayashi M, Kumada H. Long-term effects of peginterferon alfa-2a therapy in Japanese patients with chronic hepatitis B virus infection. Virol J 2015;12:225. [PMID: 26700861 DOI: 10.1186/s12985-015-0453-7] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
234 Zhang CY, Zhang Q, Zhang HM, Yang HS. 3.0T 31P MR spectroscopy in assessment of response to antiviral therapy for chronic hepatitis C. World J Gastroenterol 2014; 20(8): 2107-2112 [PMID: 24587683 DOI: 10.3748/wjg.v20.i8.2107] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
235 Son SH, Jang HS, Sung SY, Kang HJ, Lee S, Kay CS. Identifying the optimal criteria of radiotherapeutic parameters for patients with unresectable locally advanced hepatocellular carcinoma. Oncotarget 2015;6:42372-9. [PMID: 26510905 DOI: 10.18632/oncotarget.5713] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
236 Hu KQ, Pan CQ, Goodwin D. Barriers to screening for hepatitis B virus infection in Asian Americans. Dig Dis Sci 2011;56:3163-71. [PMID: 21861105 DOI: 10.1007/s10620-011-1840-6] [Cited by in Crossref: 48] [Cited by in F6Publishing: 47] [Article Influence: 4.8] [Reference Citation Analysis]
237 Choi J, Kim HJ, Lee J, Cho S, Ko MJ, Lim YS. Risk of Hepatocellular Carcinoma in Patients Treated with Entecavir vs Tenofovir for Chronic Hepatitis B: A Korean Nationwide Cohort Study. JAMA Oncol. 2019;5:30-36. [PMID: 30267080 DOI: 10.1001/jamaoncol.2018.4070] [Cited by in Crossref: 108] [Cited by in F6Publishing: 99] [Article Influence: 54.0] [Reference Citation Analysis]
238 Tsai SH, Dai MS, Yu JC, Ho CL, Chen YC, Wu YY, Chang PY, Kao WY, Chao TY. Preventing chemotherapy-induced hepatitis B reactivation in breast cancer patients: a prospective comparison of prophylactic versus deferred preemptive lamivudine. Support Care Cancer 2011;19:1779-87. [PMID: 20927554 DOI: 10.1007/s00520-010-1019-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
239 Kwon SY, Lee CH. Epidemiology and prevention of hepatitis B virus infection. Korean J Hepatol. 2011;17:87-95. [PMID: 21757978 DOI: 10.3350/kjhep.2011.17.2.87] [Cited by in Crossref: 51] [Cited by in F6Publishing: 45] [Article Influence: 5.1] [Reference Citation Analysis]
240 Khorsandi SE, Heaton N. Contemporary strategies in the management of hepatocellular carcinoma. HPB Surg 2012;2012:154056. [PMID: 23197879 DOI: 10.1155/2012/154056] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
241 Lok AS. Personalized treatment of hepatitis B. Clin Mol Hepatol. 2015;21:1-6. [PMID: 25834795 DOI: 10.3350/cmh.2015.21.1.1] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
242 Robotin MC. Hepatitis B prevention and control: Lessons from the East and the West. World J Hepatol 2011; 3(2): 31-37 [PMID: 21423912 DOI: 10.4254/wjh.v3.i2.31] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
243 Iimuro Y, Yada A, Okada T, Nakamura I, Suzumura K, Xu J, Sudo M, Nishiguchi S, Kawada N, Hatano E, Fujimoto J. Cytoglobin-expressing cells in the splenic cords contribute to splenic fibrosis in cirrhotic patients. Histol Histopathol 2020;35:1319-28. [PMID: 32945524 DOI: 10.14670/HH-18-257] [Reference Citation Analysis]
244 Uribe LA, Nguyen N, Kim L, Trinh HN, Wong C, Wong C, Nguyen LH, Nguyen MH. Rates of Treatment Eligibility in Follow-Up of Patients with Chronic Hepatitis B (CHB) Across Various Clinical Settings Who Were Initially Ineligible at Presentation. Dig Dis Sci 2016;61:618-25. [PMID: 26660679 DOI: 10.1007/s10620-015-3982-4] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
245 Lu SY, Hua J, Xu J, Wei MY, Liang C, Meng QC, Liu J, Zhang B, Wang W, Yu XJ, Shi S. Microorganisms in chemotherapy for pancreatic cancer: An overview of current research and future directions. Int J Biol Sci 2021;17:2666-82. [PMID: 34326701 DOI: 10.7150/ijbs.59117] [Reference Citation Analysis]
246 Wu H, Yim C, Chan A, Ho M, Heathcote J. Sociocultural factors that potentially affect the institution of prevention and treatment strategies for prevention of hepatitis B in Chinese Canadians. Can J Gastroenterol 2009;23:31-6. [PMID: 19172206 DOI: 10.1155/2009/608352] [Cited by in Crossref: 42] [Cited by in F6Publishing: 41] [Article Influence: 3.5] [Reference Citation Analysis]
247 Nagata N, Kagawa T, Hirose S, Arase Y, Tsuruya K, Anzai K, Shiraishi K, Mine T. Off-treatment durability of antiviral response to nucleoside analogues in patients with chronic hepatitis B. BMC Gastroenterol 2016;16:38. [PMID: 26987437 DOI: 10.1186/s12876-016-0454-z] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
248 Lin MT, Chou YP, Hu TH, Yu HC, Hsu YC, Tsai MC, Tseng PL, Chang KC, Yen YH, Chiu KW. Telbivudine and adefovir combination therapy for patients with chronic lamivudine-resistant hepatitis B virus infections. Arch Virol. 2014;159:29-37. [PMID: 23857507 DOI: 10.1007/s00705-013-1786-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
249 Cheng R, Xu J, Tan N, Luo H, Pan J, Xu X. Predictive Nomograms for Clinical Outcomes in Hepatitis B-Related Cirrhosis Patients Receiving Antiviral Therapy. Infect Drug Resist 2021;14:2707-19. [PMID: 34290509 DOI: 10.2147/IDR.S316026] [Reference Citation Analysis]
250 Kubo S, Takemura S, Tanaka S, Shinkawa H, Nishioka T, Nozawa A, Kinoshita M, Hamano G, Ito T, Urata Y. Management of hepatitis B virus infection during treatment for hepatitis B virus-related hepatocellular carcinoma. World J Gastroenterol 2015; 21(27): 8249-8255 [PMID: 26217076 DOI: 10.3748/wjg.v21.i27.8249] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.7] [Reference Citation Analysis]
251 Fitzmorris P, Shoreibah M, Anand BS, Singal AK. Management of hepatocellular carcinoma. J Cancer Res Clin Oncol 2015;141:861-76. [DOI: 10.1007/s00432-014-1806-0] [Cited by in Crossref: 59] [Cited by in F6Publishing: 67] [Article Influence: 8.4] [Reference Citation Analysis]
252 Nahon P, Vo Quang E, Ganne-Carrié N. Stratification of Hepatocellular Carcinoma Risk Following HCV Eradication or HBV Control. J Clin Med 2021;10:353. [PMID: 33477752 DOI: 10.3390/jcm10020353] [Reference Citation Analysis]
253 Dhanasekaran R, Limaye A, Cabrera R. Hepatocellular carcinoma: current trends in worldwide epidemiology, risk factors, diagnosis, and therapeutics. Hepat Med. 2012;4:19-37. [PMID: 24367230 DOI: 10.2147/hmer.s16316] [Cited by in Crossref: 39] [Cited by in F6Publishing: 132] [Article Influence: 4.3] [Reference Citation Analysis]
254 Seetharam A, Lisker-Melman M. Treatment of chronic hepatitis B: are we ready for combination therapy? Curr Gastroenterol Rep 2009;11:22-7. [PMID: 19166655 DOI: 10.1007/s11894-009-0004-8] [Reference Citation Analysis]
255 Robotin MC, George J. Community-based hepatitis B screening: what works? Hepatol Int 2014;8:478-92. [PMID: 25298848 DOI: 10.1007/s12072-014-9562-4] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 3.4] [Reference Citation Analysis]
256 Abaalkhail F, Elsiesy H, AlOmair A, Alghamdi MY, Alalwan A, AlMasri N, Al-Hamoudi W; Saudi Association for the Study of Liver Diseases and Transplantation (SASLT). SASLT practice guidelines for the management of hepatitis B virus. Saudi J Gastroenterol 2014;20:5-25. [PMID: 24496154 DOI: 10.4103/1319-3767.126311] [Cited by in Crossref: 13] [Cited by in F6Publishing: 18] [Article Influence: 1.9] [Reference Citation Analysis]
257 Bolukbas C, Bolukbas FF, Kendir T, Akbayir N, Ince AT, Abut E, Horoz M, Dalay AR, Sokmen MH, Ovunc O. The effectiveness of lamivudine treatment in cirrhotic patients with HBV precore mutations: a prospective, open-label study. Dig Dis Sci. 2006;51:1196-1202. [PMID: 16944009 DOI: 10.1007/s10620-006-8032-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.1] [Reference Citation Analysis]
258 Shaikh T, Cooper C. Reassessing the role for lamivudine in chronic hepatitis B infection: a four-year cohort analysis. Can J Gastroenterol 2012;26:148-50. [PMID: 22408765 DOI: 10.1155/2012/936259] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
259 Papatheodoridis GV, Manolakopoulos S, Archimandritis AJ. Current treatment indications and strategies in chronic hepatitis B virus infection. World J Gastroenterol 2008; 14(45): 6902-6910 [PMID: 19058323 DOI: 10.3748/wjg.14.6902] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 25] [Article Influence: 1.6] [Reference Citation Analysis]
260 Lau DT, Bleibel W. Current status of antiviral therapy for hepatitis B. Therap Adv Gastroenterol. 2008;1:61-75. [PMID: 21180515 DOI: 10.1177/1756283x08093944] [Cited by in Crossref: 17] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
261 Juday T, Tang H, Harris M, Powers AZ, Kim E, Hanna GJ. Adherence to chronic hepatitis B treatment guideline recommendations for laboratory monitoring of patients who are not receiving antiviral treatment. J Gen Intern Med 2011;26:239-44. [PMID: 20978862 DOI: 10.1007/s11606-010-1549-9] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 1.8] [Reference Citation Analysis]
262 Bedre RH, Raj U, Misra SP, Varadwaj PK. Antiviral therapy with nucleotide/nucleoside analogues in chronic hepatitis B: A meta-analysis of prospective randomized trials. Indian J Gastroenterol 2016;35:75-82. [PMID: 27083430 DOI: 10.1007/s12664-016-0632-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
263 Chang SW, Fann CS, Su WH, Wang YC, Weng CC, Yu CJ, Hsu CL, Hsieh AR, Chien RN, Chu CM. A genome-wide association study on chronic HBV infection and its clinical progression in male Han-Taiwanese. PLoS One. 2014;9:e99724. [PMID: 24940741 DOI: 10.1371/journal.pone.0099724] [Cited by in Crossref: 35] [Cited by in F6Publishing: 34] [Article Influence: 5.0] [Reference Citation Analysis]
264 Wang D, Wang Q, Shan F, Liu B, Lu C. Identification of the risk for liver fibrosis on CHB patients using an artificial neural network based on routine and serum markers. BMC Infect Dis. 2010;10:251. [PMID: 20735842 DOI: 10.1186/1471-2334-10-251] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 2.0] [Reference Citation Analysis]
265 Wang CC, Lin CL, Hsieh TY, Tseng KC, Peng CY, Su TH, Yang SS, Hsu YC, Chen TM, Kao JH. Efficacy and resistance to telbivudine treatment in chronic hepatitis B patients with favorable predictors: a multicenter study in Taiwan. Hepatol Int 2016;10:294-301. [PMID: 26399763 DOI: 10.1007/s12072-015-9662-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
266 Toy M, Onder FO, Idilman R, Kabacam G, Richardus JH, Bozdayi M, Akdogan M, Kuloglu Z, Kansu A, Schalm S, Yurdaydin C. The cost-effectiveness of treating chronic hepatitis B patients in a median endemic and middle income country. Eur J Health Econ 2012;13:663-76. [PMID: 22815098 DOI: 10.1007/s10198-012-0413-8] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.1] [Reference Citation Analysis]
267 Teng W, Liu YC, Jeng WJ, Su CW. Tertiary Prevention of HCC in Chronic Hepatitis B or C Infected Patients. Cancers (Basel) 2021;13:1729. [PMID: 33917345 DOI: 10.3390/cancers13071729] [Reference Citation Analysis]
268 Kim HJ, Park SK, Yang HJ, Jung YS, Park JH, Park DI, Cho YK, Sohn CI, Jeon WK, Kim BI, Choi KY. Comparison of the clinical outcomes between antiviral-naïve patients treated with entecavir and lamivudine-resistant patients receiving adefovir add-on lamivudine combination treatment. Clin Mol Hepatol 2016;22:350-8. [PMID: 27729626 DOI: 10.3350/cmh.2016.0019] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
269 朱传武, 王海燕, 方焕. 乙型肝炎肝硬化的抗病毒治疗. 世界华人消化杂志 2011; 19(15): 1592-1597 [DOI: 10.11569/wcjd.v19.i15.1592] [Reference Citation Analysis]
270 Kuo YH, Lu SN, Chen CH, Chang KC, Hung CH, Tai WC, Tsai MC, Tseng PL, Hu TH, Wang JH. The changes of liver stiffness and its associated factors for chronic hepatitis B patients with entecavir therapy. PLoS One. 2014;9:e93160. [PMID: 24682088 DOI: 10.1371/journal.pone.0093160] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 3.1] [Reference Citation Analysis]
271 Tiwari AK, Laird-Fick HS, Wali RK, Roy HK. Surveillance for gastrointestinal malignancies. World J Gastroenterol 2012; 18(33): 4507-4516 [PMID: 22969223 DOI: 10.3748/wjg.v18.i33.4507] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
272 Thibault V, Pichoud C, Mullen C, Rhoads J, Smith JB, Bitbol A, Thamm S, Zoulim F. Characterization of a new sensitive PCR assay for quantification of viral DNA isolated from patients with hepatitis B virus infections. J Clin Microbiol. 2007;45:3948-3953. [PMID: 17942654 DOI: 10.1128/jcm.01180-07] [Cited by in Crossref: 35] [Cited by in F6Publishing: 12] [Article Influence: 2.5] [Reference Citation Analysis]
273 Tsai TY, Hung TH, Livneh H, Lin IH, Lu MC, Yeh CC. Chinese herbal medicine therapy and the risk of mortality for chronic hepatitis B patients with concurrent liver cirrhosis: a nationwide population-based cohort study. Oncotarget 2018;9:18214-23. [PMID: 29719600 DOI: 10.18632/oncotarget.24383] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
274 Jwa HY, Cho YK, Choi EK, Kim HU, Song HJ, Na SY, Boo SJ, Jeong SU, Kim BS, Lee BW, Song BC. Regression of esophageal varices during entecavir treatment in patients with hepatitis-B-virus-related liver cirrhosis. Clin Mol Hepatol 2016;22:183-7. [PMID: 27044771 DOI: 10.3350/cmh.2016.22.1.183] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
275 Liu CJ, Chen PJ. Elimination of Hepatitis B in Highly Endemic Settings: Lessons Learned in Taiwan and Challenges Ahead. Viruses 2020;12:E815. [PMID: 32731536 DOI: 10.3390/v12080815] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
276 Ghany MG, Doo EC. Antiviral resistance and hepatitis B therapy. Hepatology. 2009;49:S174-S184. [PMID: 19399794 DOI: 10.1002/hep.22900] [Cited by in Crossref: 142] [Cited by in F6Publishing: 139] [Article Influence: 11.8] [Reference Citation Analysis]
277 Xu XY, Kong H, Song RX, Zhai YH, Wu XF, Ai WS, Liu HB. The effectiveness of noninvasive biomarkers to predict hepatitis B-related significant fibrosis and cirrhosis: a systematic review and meta-analysis of diagnostic test accuracy. PLoS One. 2014;9:e100182. [PMID: 24964038 DOI: 10.1371/journal.pone.0100182] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 3.6] [Reference Citation Analysis]
278 Yang J, Chen G, Chen X, Zhang H, Jiang D, Yang G. Initial combination anti-viral therapy with lamivudine and adefovir dipivoxil decreases short-term fatality rate of hepatitis-B-virus-related acute-on-chronic liver failure. Virol J. 2015;12:97. [PMID: 26104153 DOI: 10.1186/s12985-015-0323-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
279 Hu J, Wang Z, Fan J, Dai Z, He YF, Qiu SJ, Huang XW, Sun J, Xiao YS, Song K, Shi YH, Sun QM, Yang XR, Shi GM, Yu L, Yang GH, Ding ZB, Gao Q, Tang ZY, Zhou J. Genetic variations in plasma circulating DNA of HBV-related hepatocellular carcinoma patients predict recurrence after liver transplantation. PLoS One 2011;6:e26003. [PMID: 21998744 DOI: 10.1371/journal.pone.0026003] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
280 Lee YB, Jung EU, Kim BH, Lee JH, Cho H, Ahn H, Choi WM, Cho YY, Lee M, Yoo JJ. Tenofovir monotherapy versus tenofovir plus lamivudine or telbivudine combination therapy in treatment of lamivudine-resistant chronic hepatitis B. Antimicrob Agents Chemother. 2015;59:972-978. [PMID: 25421484 DOI: 10.1128/AAC.04454-14] [Cited by in Crossref: 16] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
281 Koziel MJ, Peters MG. Viral hepatitis in HIV infection. N Engl J Med. 2007;356:1445-1454. [PMID: 17409326 DOI: 10.1056/nejmra065142] [Cited by in Crossref: 195] [Cited by in F6Publishing: 87] [Article Influence: 13.9] [Reference Citation Analysis]
282 Zhu A, Liao X, Li S, Zhao H, Chen L, Xu M, Duan X. HBV cccDNA and Its Potential as a Therapeutic Target. J Clin Transl Hepatol 2019;7:258-62. [PMID: 31608218 DOI: 10.14218/JCTH.2018.00054] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
283 Akbar SM, Al-Mahtab M, Hiasa Y. Future aspects of therapy for hepatitis B virus infection: value of surrogate markers, innovative therapy, and global collaboration. J Gastroenterol 2011;46:717-23. [PMID: 21526371 DOI: 10.1007/s00535-011-0401-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
284 Treem WR, Palmer M, Lonjon-Domanec I, Seekins D, Dimick-Santos L, Avigan MI, Marcinak JF, Dash A, Regev A, Maller E, Patwardhan M, Lewis JH, Rockey DC, Di Bisceglie AM, Freston JW, Andrade RJ, Chalasani N. Consensus Guidelines: Best Practices for Detection, Assessment and Management of Suspected Acute Drug-Induced Liver Injury During Clinical Trials in Adults with Chronic Viral Hepatitis and Adults with Cirrhosis Secondary to Hepatitis B, C and Nonalcoholic Steatohepatitis. Drug Saf 2021;44:133-65. [PMID: 33141341 DOI: 10.1007/s40264-020-01014-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
285 Sun P, Dong X, Cheng X, Hu Q, Zheng Q. Nucleot(s)ide analogues for hepatitis B virus-related hepatocellular carcinoma after curative treatment: a systematic review and meta-analysis. PLoS One. 2014;9:e102761. [PMID: 25058587 DOI: 10.1371/journal.pone.0102761] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 4.1] [Reference Citation Analysis]
286 Ferrarese A, Zanetto A, Gambato M, Bortoluzzi I, Nadal E, Germani G, Senzolo M, Burra P, Russo FP. Liver transplantation for viral hepatitis in 2015. World J Gastroenterol 2016; 22(4): 1570-1581 [PMID: 26819523 DOI: 10.3748/wjg.v22.i4.1570] [Cited by in CrossRef: 23] [Cited by in F6Publishing: 19] [Article Influence: 4.6] [Reference Citation Analysis]
287 Sherman AC, Trehanpati N, Daucher M, Davey RT, Masur H, Sarin SK, Kottilil S, Kohli A. Augmentation of hepatitis B virus-specific cellular immunity with programmed death receptor-1/programmed death receptor-L1 blockade in hepatitis B virus and HIV/hepatitis B virus coinfected patients treated with adefovir. AIDS Res Hum Retroviruses. 2013;29:665-672. [PMID: 23259453 DOI: 10.1089/AID.2012.0320] [Cited by in Crossref: 20] [Cited by in F6Publishing: 24] [Article Influence: 2.5] [Reference Citation Analysis]
288 Maresso KC, Tsai KY, Brown PH, Szabo E, Lippman S, Hawk ET. Molecular cancer prevention: Current status and future directions. CA Cancer J Clin 2015;65:345-83. [PMID: 26284997 DOI: 10.3322/caac.21287] [Cited by in Crossref: 43] [Cited by in F6Publishing: 43] [Article Influence: 7.2] [Reference Citation Analysis]
289 Jie Y, Li X, Lin G, Wu Y, Li X, Gao Z, Chong Y. Real-life practice of antiviral therapy and disease patterns of patients with chronic hepatitis B: a single-center retrospective observation study. Hepatol Int 2014;8:501-7. [PMID: 26202755 DOI: 10.1007/s12072-014-9551-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
290 Wang XL, Xie SG, Zhang L, Yang WX, Wang X, Jin HZ. Comparison of ligase detection reaction and real-time PCR for detection of low abundant YMDD mutants in patients with chronic hepatitis B. World J Gastroenterol 2008; 14(1): 120-124 [PMID: 18176973 DOI: 10.3748/wjg.14.120] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
291 Yonezawa S, Koide H, Asai T. Recent advances in siRNA delivery mediated by lipid-based nanoparticles. Adv Drug Deliv Rev 2020;154-155:64-78. [PMID: 32768564 DOI: 10.1016/j.addr.2020.07.022] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 22.0] [Reference Citation Analysis]
292 Buti M, Oyagüez I, Lozano V, Casado MA. Cost effectiveness of first-line oral antiviral therapies for chronic hepatitis B: a systematic review. Pharmacoeconomics. 2013;31:63-75. [PMID: 23329593 DOI: 10.1007/s40273-012-0009-2] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
293 Kim SS, Cheong JY, Cho SW. Current Nucleos(t)ide Analogue Therapy for Chronic Hepatitis B. Gut Liver 2011;5:278-87. [PMID: 21927654 DOI: 10.5009/gnl.2011.5.3.278] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
294 Andersson KL, Chung RT. Monitoring during and after antiviral therapy for hepatitis B. Hepatology 2009;49:S166-73. [PMID: 19399793 DOI: 10.1002/hep.22899] [Cited by in Crossref: 36] [Cited by in F6Publishing: 31] [Article Influence: 3.0] [Reference Citation Analysis]
295 Lim YS. Management of Antiviral Resistance in Chronic Hepatitis B. Gut Liver 2017;11:189-95. [PMID: 28183162 DOI: 10.5009/gnl15562] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 6.3] [Reference Citation Analysis]
296 Kurokawa M, Hiramatsu N, Oze T, Yakushijin T, Miyazaki M, Hosui A, Miyagi T, Yoshida Y, Ishida H, Tatsumi T, Kiso S, Kanto T, Kasahara A, Iio S, Doi Y, Yamada A, Oshita M, Kaneko A, Mochizuki K, Hagiwara H, Mita E, Ito T, Inui Y, Katayama K, Yoshihara H, Imai Y, Hayashi E, Hayashi N, Takehara T. Long-term effect of lamivudine treatment on the incidence of hepatocellular carcinoma in patients with hepatitis B virus infection. J Gastroenterol 2012;47:577-85. [PMID: 22231575 DOI: 10.1007/s00535-011-0522-7] [Cited by in Crossref: 45] [Cited by in F6Publishing: 48] [Article Influence: 5.0] [Reference Citation Analysis]
297 Sohn HR, Min BY, Song JC, Seong MH, Lee SS, Jang ES, Shin CM, Park YS, Hwang JH, Jeong SH, Kim N, Lee DH, Kim JW. Off-treatment virologic relapse and outcomes of re-treatment in chronic hepatitis B patients who achieved complete viral suppression with oral nucleos(t)ide analogs. BMC Infect Dis. 2014;14:439. [PMID: 25125320 DOI: 10.1186/1471-2334-14-439] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 4.7] [Reference Citation Analysis]
298 Niederau C. [New data and recommendations of antiviral therapy of chronic hepatitis B and C]. Internist (Berl) 2008;49:1265-6, 1268-73. [PMID: 18340426 DOI: 10.1007/s00108-008-2037-8] [Reference Citation Analysis]
299 Saab S, Rheem J, Jimenez MA, Fong TM, Mai MH, Kachadoorian CA, Esmailzadeh NL, Bau SN, Kang S, Ramirez SD, Grotts J, Choi G, Durazo FA, El-Kabany MM, Han SB, Busuttil RW. Effectiveness of Ledipasvir/Sofosbuvir with/without Ribavarin in Liver Transplant Recipients with Hepatitis C. J Clin Transl Hepatol 2017;5:101-8. [PMID: 28660147 DOI: 10.14218/JCTH.2016.00070] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
300 Shamliyan TA, Johnson JR, MacDonald R, Shaukat A, Yuan JM, Kane RL, Wilt TJ. Systematic review of the literature on comparative effectiveness of antiviral treatments for chronic hepatitis B infection. J Gen Intern Med 2011;26:326-39. [PMID: 21203860 DOI: 10.1007/s11606-010-1569-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
301 Wang B, Agarwal K, Joshi D. Management of chronic hepatitis B before and after liver transplantation. Frontline Gastroenterol 2018;9:79-84. [PMID: 29484165 DOI: 10.1136/flgastro-2016-100768] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
302 Coffin CS, Fung SK, Ma MM; Canadian Association for the Study of the Liver. Management of chronic hepatitis B: Canadian Association for the Study of the Liver consensus guidelines. Can J Gastroenterol 2012;26:917-38. [PMID: 23248795 DOI: 10.1155/2012/506819] [Cited by in Crossref: 38] [Cited by in F6Publishing: 41] [Article Influence: 4.8] [Reference Citation Analysis]
303 de Fraga RS, Van Vaisberg V, Mendes LCA, Carrilho FJ, Ono SK. Adverse events of nucleos(t)ide analogues for chronic hepatitis B: a systematic review. J Gastroenterol 2020;55:496-514. [PMID: 32185517 DOI: 10.1007/s00535-020-01680-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
304 Thiele M, Gluud LL, Fialla AD, Dahl EK, Krag A. Large variations in risk of hepatocellular carcinoma and mortality in treatment naïve hepatitis B patients: systematic review with meta-analyses. PLoS One. 2014;9:e107177. [PMID: 25225801 DOI: 10.1371/journal.pone.0107177] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 3.3] [Reference Citation Analysis]
305 Yang ZJ, Tu MZ, Liu J, Wang XL, Jin HZ. Comparison of amplicon-sequencing, pyrosequencing and real-time PCR for detection of YMDD mutants in patients with chronic hepatitis B. World J Gastroenterol 2006; 12(44): 7192-7196 [PMID: 17131486 DOI: 10.3748/wjg.v12.i44.7192] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
306 Jin M, Chen Y, Hu S, Zhu M, Wang Y, Chen M, Peng Z. Association of Virological Response to Antiviral Therapy With Survival in Intermediate-Stage Hepatitis B Virus-Related Hepatocellular Carcinoma After Chemoembolization. Front Oncol 2021;11:751777. [PMID: 34745980 DOI: 10.3389/fonc.2021.751777] [Reference Citation Analysis]
307 Moon JC, Kim SH, Kim IH, Lee CH, Kim SW, Lee SO, Lee ST, Kim DG. Disease Progression in Chronic Hepatitis B Patients under Long-Term Antiviral Therapy. Gut Liver. 2015;9:395-404. [PMID: 25473072 DOI: 10.5009/gnl14170] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
308 Lee CZ, Lee HS, Huang GT, Yang PM, Sheu JC. Detection of YMDD mutation using mutant-specific primers in chronic hepatitis B patients before and after lamivudine treatment. World J Gastroenterol 2006; 12(33): 5301-5305 [PMID: 16981258 DOI: 10.3748/wjg.v12.i33.5301] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 12] [Article Influence: 0.7] [Reference Citation Analysis]
309 Kim JH, Sinn DH, Kim K, Kim H, Gwak GY, Paik YH, Choi MS, Lee JH, Koh KC, Paik SW. Lamivudine versus Entecavir for Newly Diagnosed Hepatitis B Virus-Related Hepatocellular Carcinoma. Gut Liver 2016;10:939-47. [PMID: 27282264 DOI: 10.5009/gnl15527] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
310 Reijnders JG, LA Janssen H. New approaches in the management of chronic hepatitis B: role of tenofovir. Infect Drug Resist 2009;2:13-26. [PMID: 21694884 DOI: 10.2147/idr.s3918] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
311 Şahin A, Namıduru M, Balkan A, Karaoğlan İ, Gülşen MT. Assessment of histopathological alterations in patients with chronic hepatitis B infection following long-term oral antiviral therapy. Saudi Med J 2018;39:999-1005. [PMID: 30284582 DOI: 10.15537/smj.2018.10.23056] [Reference Citation Analysis]
312 Arteaga CL, Adamson PC, Engelman JA, Foti M, Gaynor RB, Hilsenbeck SG, Limburg PJ, Lowe SW, Mardis ER, Ramsey S, Rebbeck TR, Richardson AL, Rubin EH, Weiner GJ. AACR Cancer Progress Report 2014. Clin Cancer Res 2014;20:S1-S112. [PMID: 25228531 DOI: 10.1158/1078-0432.CCR-14-2123] [Cited by in Crossref: 39] [Cited by in F6Publishing: 15] [Article Influence: 5.6] [Reference Citation Analysis]
313 Han SH, Reddy KR, Keeffe EB, Soldevila-Pico C, Gish R, Chung RT, Degertekin B, Lok A; NIH HBV OLT Study Group. Clinical outcomes of liver transplantation for HBV-related hepatocellular carcinoma: data from the NIH HBV OLT study. Clin Transplant 2011;25:E152-62. [PMID: 21077950 DOI: 10.1111/j.1399-0012.2010.01349.x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
314 Jeon HJ, Jung SW, Park NH, Yang Y, Noh JH, Ahn JS, Kim HR, Lee JH, Shin JW. Efficacy of tenofovir-based rescue therapy for chronic hepatitis B patients with resistance to lamivudine and entecavir. Clin Mol Hepatol 2017;23:230-8. [PMID: 28669175 DOI: 10.3350/cmh.2017.0003] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
315 Pawlotsky JM, Dusheiko G, Hatzakis A, Lau D, Lau G, Liang TJ, Locarnini S, Martin P, Richman DD, Zoulim F. Virologic monitoring of hepatitis B virus therapy in clinical trials and practice: Recommendations for a standardized approach. Gastroenterology. 2008;134:405-415. [PMID: 18242209 DOI: 10.1053/j.gastro.2007.11.036] [Cited by in Crossref: 163] [Cited by in F6Publishing: 151] [Article Influence: 11.6] [Reference Citation Analysis]
316 Yuan P, Chen P, Qian Y. Evaluation of Antiviral Therapy Performed after Curative Therapy in Patients with HBV-Related Hepatocellular Carcinoma: An Updated Meta-Analysis. Can J Gastroenterol Hepatol. 2016;2016:5234969. [PMID: 27446846 DOI: 10.1155/2016/5234969] [Cited by in Crossref: 5] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
317 Xia Y, Cheng X, Li Y, Valdez K, Chen W, Liang TJ. Hepatitis B Virus Deregulates the Cell Cycle To Promote Viral Replication and a Premalignant Phenotype. J Virol 2018;92:e00722-18. [PMID: 30021897 DOI: 10.1128/JVI.00722-18] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 6.7] [Reference Citation Analysis]
318 Schinazi RF, Ehteshami M, Bassit L, Asselah T. Towards HBV curative therapies. Liver Int 2018;38 Suppl 1:102-14. [PMID: 29427479 DOI: 10.1111/liv.13656] [Cited by in Crossref: 38] [Cited by in F6Publishing: 36] [Article Influence: 19.0] [Reference Citation Analysis]
319 Wright CM, Boudarène L, Ha NT, Wu O, Hawkins N. A systematic review of hepatitis B screening economic evaluations in low- and middle-income countries. BMC Public Health 2018;18:373. [PMID: 29558894 DOI: 10.1186/s12889-018-5261-8] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
320 Suk KT, Baik SK, Yoon JH, Cheong JY, Paik YH, Lee CH, Kim YS, Lee JW, Kim DJ, Cho SW, Hwang SG, Sohn JH, Kim MY, Kim YB, Kim JG, Cho YK, Choi MS, Kim HJ, Lee HW, Kim SU, Kim JK, Choi JY, Jun DW, Tak WY, Lee BS, Jang BK, Chung WJ, Kim HS, Jang JY, Jeong SW, Kim SG, Kwon OS, Jung YK, Choe WH, Lee JS, Kim IH, Shim JJ, Cheon GJ, Bae SH, Seo YS, Choi DH, Jang SJ; Korean Association for the Study of the Liver. Revision and update on clinical practice guideline for liver cirrhosis. Korean J Hepatol. 2012;18:1-21. [PMID: 22511898 DOI: 10.3350/kjhep.2012.18.1.1] [Cited by in Crossref: 94] [Cited by in F6Publishing: 87] [Article Influence: 10.4] [Reference Citation Analysis]
321 Fung J, Lai CL, Yuen MF, Ng IO. Do statins reduce the risk of hepatocellular carcinoma in patients with chronic hepatitis B? Hepatobiliary Surg Nutr 2013;2:34-6. [PMID: 24570913 DOI: 10.3978/j.issn.2304-3881.2012.10.04] [Reference Citation Analysis]
322 Massarweh NN, El-Serag HB. Epidemiology of Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma. Cancer Control. 2017;24:1073274817729245. [PMID: 28975830 DOI: 10.1177/1073274817729245] [Cited by in Crossref: 155] [Cited by in F6Publishing: 155] [Article Influence: 51.7] [Reference Citation Analysis]
323 Bi J, Zhang Z, Qin E, Hou J, Liu S, Liu Z, Li S, Wei Z, Zhong Y. Nucleoside analogs treatment delay the onset of hepatocellular carcinoma in patients with HBV-related cirrhosis. Oncotarget 2017;8:96725-31. [PMID: 29228565 DOI: 10.18632/oncotarget.18075] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
324 Eckman MH, Kaiser TE, Sherman KE. The cost-effectiveness of screening for chronic hepatitis B infection in the United States. Clin Infect Dis. 2011;52:1294-1306. [PMID: 21540206 DOI: 10.1093/cid/cir199] [Cited by in Crossref: 55] [Cited by in F6Publishing: 56] [Article Influence: 5.5] [Reference Citation Analysis]
325 Kuo WL, Yu MC, Lee JF, Tsai CN, Chen TC, Chen MF. Imatinib mesylate improves liver regeneration and attenuates liver fibrogenesis in CCL4-treated mice. J Gastrointest Surg 2012;16:361-9. [PMID: 22068968 DOI: 10.1007/s11605-011-1764-7] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
326 Fan XH, Geng JZ, Wang LF, Zheng YY, Lu HY, Li J, Xu XY. De novo combination therapy with lamivudine and adefovir dipivoxil in chronic hepatitis B patients. World J Gastroenterol 2011; 17(43): 4804-4809 [PMID: 22147982 DOI: 10.3748/wjg.v17.i43.4804] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
327 Udompap P, Kim WR. Development of Hepatocellular Carcinoma in Patients With Suppressed Viral Replication: Changes in Risk Over Time. Clin Liver Dis (Hoboken) 2020;15:85-90. [PMID: 32226623 DOI: 10.1002/cld.904] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 6.0] [Reference Citation Analysis]
328 Michielsen PP, Francque SM, van Dongen JL. Viral hepatitis and hepatocellular carcinoma. World J Surg Oncol. 2005;3:27. [PMID: 15907199 DOI: 10.1186/1477-7819-3-27] [Cited by in Crossref: 85] [Cited by in F6Publishing: 82] [Article Influence: 5.3] [Reference Citation Analysis]
329 Tsai N, Jeffers L, Cragin L, Sorensen S, Su W, Rosenblatt L, Tang H, Hebden T, Juday T. Cost-effectiveness of entecavir versus adefovir for the treatment of chronic hepatitis B in patients with decompensated cirrhosis from a third-party US payer perspective. Clinicoecon Outcomes Res. 2012;4:227-235. [PMID: 22977309 DOI: 10.2147/ceor.s31784] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
330 Manzoor S, Saalim M, Imran M, Resham S, Ashraf J. Hepatitis B virus therapy: What’s the future holding for us? World J Gastroenterol 2015; 21(44): 12558-12575 [PMID: 26640332 DOI: 10.3748/wjg.v21.i44.12558] [Cited by in CrossRef: 27] [Cited by in F6Publishing: 25] [Article Influence: 4.5] [Reference Citation Analysis]
331 Kim JK, Ma DW, Lee KS, Paik YH. Assessment of hepatic fibrosis regression by transient elastography in patients with chronic hepatitis B treated with oral antiviral agents. J Korean Med Sci 2014;29:570-5. [PMID: 24753706 DOI: 10.3346/jkms.2014.29.4.570] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
332 Karayiannis P. Direct acting antivirals for the treatment of chronic viral hepatitis. Scientifica (Cairo) 2012;2012:478631. [PMID: 24278700 DOI: 10.6064/2012/478631] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
333 Yu LH, Li N, Cheng SQ. The Role of Antiviral Therapy for HBV-Related Hepatocellular Carcinoma. Int J Hepatol. 2011;2011:416459. [PMID: 21994855 DOI: 10.4061/2011/416459] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
334 Song BC, Cho YK, Jwa H, Choi EK, Kim HU, Song HJ, Na SY, Boo SJ, Jeong SU. Is it necessary to delay antiviral therapy for 3-6 months to anticipate HBeAg seroconversion in patients with HBeAg-positive chronic hepatitis B in endemic areas of HBV genotype C? Clin Mol Hepatol 2014;20:355-60. [PMID: 25548741 DOI: 10.3350/cmh.2014.20.4.355] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
335 Li Y, Chen Y, Zhao Y. The diagnostic value of the FIB-4 index for staging hepatitis B-related fibrosis: a meta-analysis. PLoS One. 2014;9:e105728. [PMID: 25165830 DOI: 10.1371/journal.pone.0105728] [Cited by in Crossref: 43] [Cited by in F6Publishing: 42] [Article Influence: 6.1] [Reference Citation Analysis]
336 Gao W, Fan YC, Zhang JY, Zheng MH. Emerging Role of Interleukin 22 in Hepatitis B Virus Infection: a Double-edged Sword. J Clin Transl Hepatol 2013;1:103-8. [PMID: 26356012 DOI: 10.14218/JCTH.2013.00013] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
337 Tien TV, Pho DC, Hong LT, Ba HP, Nam LV, Hung PN. Antiretroviral drug resistance mutations among patients failing first-line treatment in Hanoi, Vietnam. Infect Drug Resist 2019;12:1237-42. [PMID: 31190911 DOI: 10.2147/IDR.S196448] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
338 Yao G, Chen C, Lu W, Ren H, Tan D, Wang Y, Xu D, Liu J, Xu D, Llamoso C. Virologic, serologic, and biochemical outcomes through 2 years of treatment with entecavir and lamivudine in nucleoside-naïve Chinese patients with chronic hepatitis B: a randomized, multicenter study. Hepatol Int. 2008;2:486-493. [PMID: 19669324 DOI: 10.1007/s12072-008-9088-8] [Cited by in Crossref: 15] [Cited by in F6Publishing: 21] [Article Influence: 1.2] [Reference Citation Analysis]
339 宋健, 钟慧闽, 朱寿美, 姚萍, 杨杰. 苦参素联合拉米夫定治疗乙型肝炎早期肝硬化33例. 世界华人消化杂志 2008; 16(10): 1124-1127 [DOI: 10.11569/wcjd.v16.i10.1124] [Cited by in CrossRef: 1] [Article Influence: 0.1] [Reference Citation Analysis]
340 Kwon JH, Song MJ, Jang JW, Bae SH, Choi JY, Yoon SK, Kim HY, Kim CW, Song DS, Chang UI, Yang JM, You CR, Choi SW, Lee HL, Lee SW, Han NI, Nam SW, Kim SG, Kim YS, Kim SH, Lee BS, Lee TH, Cho EY. Efficacy and Safety of Tenofovir Disoproxil Fumarate in Treatment-Naïve Patients with Chronic Hepatitis B in Korea. Dig Dis Sci 2019;64:2039-48. [PMID: 30725293 DOI: 10.1007/s10620-019-05489-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
341 Tong MJ, Rosinski AA, Huynh CT, Raman SS, Lu DSK. Long-term survival after surveillance and treatment in patients with chronic viral hepatitis and hepatocellular carcinoma. Hepatol Commun 2017;1:595-608. [PMID: 29404481 DOI: 10.1002/hep4.1047] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
342 Ramachandran J. Surveillance for hepatocellular carcinoma. J Clin Exp Hepatol. 2014;4:S50-S56. [PMID: 25755611 DOI: 10.1016/j.jceh.2014.03.050] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
343 Kumar A, Acharya SK, Singh SP, Saraswat VA, Arora A, Duseja A, Goenka MK, Jain D, Kar P, Kumar M, Kumaran V, Mohandas KM, Panda D, Paul SB, Ramachandran J, Ramesh H, Rao PN, Shah SR, Sharma H, Thandassery RB; (The INASL Task-Force on Hepatocellular Carcinoma). The Indian National Association for Study of the Liver (INASL) Consensus on Prevention, Diagnosis and Management of Hepatocellular Carcinoma in India: The Puri Recommendations. J Clin Exp Hepatol 2014;4:S3-S26. [PMID: 25755608 DOI: 10.1016/j.jceh.2014.04.003] [Cited by in Crossref: 32] [Cited by in F6Publishing: 26] [Article Influence: 4.6] [Reference Citation Analysis]
344 Liaw YF, Kao JH, Piratvisuth T, Chan HL, Chien RN, Liu CJ, Gane E, Locarnini S, Lim SG, Han KH. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatol Int. 2012;6:531-561. [PMID: 26201469 DOI: 10.1007/s12072-012-9365-4] [Cited by in Crossref: 695] [Cited by in F6Publishing: 660] [Article Influence: 77.2] [Reference Citation Analysis]
345 Davis GL, Dempster J, Meler JD, Orr DW, Walberg MW, Brown B, Berger BD, O'Connor JK, Goldstein RM. Hepatocellular carcinoma: management of an increasingly common problem. Proc (Bayl Univ Med Cent). 2008;21:266-280. [PMID: 18628926 DOI: 10.1080/08998280.2008.11928410] [Cited by in Crossref: 105] [Cited by in F6Publishing: 102] [Article Influence: 10.5] [Reference Citation Analysis]
346 Mittal S, El-Serag HB. Epidemiology of hepatocellular carcinoma: consider the population. J Clin Gastroenterol. 2013;47 Suppl:S2-S6. [PMID: 23632345 DOI: 10.1097/mcg.0b013e3182872f29] [Cited by in Crossref: 642] [Cited by in F6Publishing: 412] [Article Influence: 80.3] [Reference Citation Analysis]
347 Cui YL, Yan F, Wang YB, Song XQ, Liu L, Lei XZ, Zheng MH, Tang H, Feng P. Nucleoside analogue can improve the long-term prognosis of patients with hepatitis B virus infection-associated acute on chronic liver failure. Dig Dis Sci. 2010;55:2373-2380. [PMID: 20512414 DOI: 10.1007/s10620-010-1257-7] [Cited by in Crossref: 57] [Cited by in F6Publishing: 60] [Article Influence: 5.2] [Reference Citation Analysis]
348 Chong CCN, Wong GLH, Lai PBS. Impact of antiviral therapy on post-hepatectomy outcome for hepatitis B-related hepatocellular carcinoma. World J Gastroenterol 2014; 20(20): 6006-6012 [PMID: 24876723 DOI: 10.3748/wjg.v20.i20.6006] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
349 Gao L, Trinh HN, Li J, Nguyen MH. Tenofovir is superior to entecavir for achieving complete viral suppression in HBeAg-positive chronic hepatitis B patients with high HBV DNA. Aliment Pharmacol Ther 2014;39:629-37. [PMID: 24467455 DOI: 10.1111/apt.12629] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 3.3] [Reference Citation Analysis]
350 Su CW, Yang YY, Lin HC. Impact of etiological treatment on prognosis. Hepatol Int 2018;12:56-67. [PMID: 28702738 DOI: 10.1007/s12072-017-9807-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
351 Gish RG. Improving outcomes for patients with chronic hepatitis B. Curr Gastroenterol Rep. 2007;9:14-22. [PMID: 17335673 DOI: 10.1007/s11894-008-0016-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 0.4] [Reference Citation Analysis]
352 Chung GE, Cho EJ, Lee JH, Yoo JJ, Lee M, Cho Y, Lee DH, Kim HY, Yu SJ, Kim YJ, Yoon JH, Zoulim F. Tenofovir has inferior efficacy in adefovir-experienced chronic hepatitis B patients compared to nucleos(t)ide-naïve patients. Clin Mol Hepatol 2017;23:66-73. [PMID: 28190329 DOI: 10.3350/cmh.2016.0060] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
353 Liu R, Guo J, Lu Y, Zhang L, Shen G, Wu S, Chang M, Hu L, Hao H, Li M, Xie Y. Changes in APRI and FIB-4 in HBeAg-negative treatment-naive chronic hepatitis B patients with significant liver histological lesions receiving 5-year entecavir therapy. Clin Exp Med 2019;19:309-20. [PMID: 31111345 DOI: 10.1007/s10238-019-00560-z] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
354 Hou J, Wang G, Wang F, Cheng J, Ren H, Zhuang H, Sun J, Li L, Li J, Meng Q, Zhao J, Duan Z, Jia J, Tang H, Sheng J, Peng J, Lu F, Xie Q, Wei L; Chinese Society of Hepatology, Chinese Medical Association., Chinese Society of Infectious Diseases, Chinese Medical Association. Guideline of Prevention and Treatment for Chronic Hepatitis B (2015 Update). J Clin Transl Hepatol 2017;5:297-318. [PMID: 29226097 DOI: 10.14218/JCTH.2016.00019] [Cited by in Crossref: 109] [Cited by in F6Publishing: 59] [Article Influence: 27.3] [Reference Citation Analysis]
355 Lee HW, Kim SU, Baatarkhuu O, Park JY, Kim DY, Ahn SH, Han KH, Kim BK. Comparison between chronic hepatitis B patients with untreated immune-tolerant phase vs. those with virological response by antivirals. Sci Rep 2019;9:2508. [PMID: 30792468 DOI: 10.1038/s41598-019-39043-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
356 Liaw YF. HBeAg seroconversion as an important end point in the treatment of chronic hepatitis B. Hepatol Int 2009;3:425-33. [PMID: 19669245 DOI: 10.1007/s12072-009-9140-3] [Cited by in Crossref: 79] [Cited by in F6Publishing: 80] [Article Influence: 6.6] [Reference Citation Analysis]
357 Nagao Y, Kimura T, Nagao H. Analysis of hepatitis B and C virus infections amongst members of the Dental National Health Insurance Society in the Oita Prefecture. Biomed Rep 2021;14:23. [PMID: 33335729 DOI: 10.3892/br.2020.1399] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
358 Su MH, Lu AL, Li SH, Zhong SH, Wang BJ, Wu XL, Mo YY, Liang P, Liu ZH, Xie R, He LX, Fu WD, Jiang JN. Long-term lamivudine for chronic hepatitis B and cirrhosis: A real-life cohort study. World J Gastroenterol 2015; 21(46): 13087-13094 [PMID: 26673249 DOI: 10.3748/wjg.v21.i46.13087] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
359 Singh S, Singh PP, Roberts LR, Sanchez W. Chemopreventive strategies in hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2014;11:45-54. [PMID: 23938452 DOI: 10.1038/nrgastro.2013.143] [Cited by in Crossref: 185] [Cited by in F6Publishing: 168] [Article Influence: 23.1] [Reference Citation Analysis]
360 Lai CL, Yuen MF. The saga of entecavir. Hepatol Int 2009;3:421-4. [PMID: 19669247 DOI: 10.1007/s12072-009-9138-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
361 Thursz M. Basis of HBV persistence and new treatment options. Hepatol Int. 2014;8 Suppl 2:486-491. [PMID: 26201329 DOI: 10.1007/s12072-013-9504-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
362 Lee HA, Seo YS, Park SW, Park SJ, Kim TH, Suh SJ, Jung YK, Kim JH, An H, Yim HJ, Yeon JE, Byun KS, Um SH. Hepatitis B surface antigen titer is a good indicator of durable viral response after entecavir off-treatment for chronic hepatitis B. Clin Mol Hepatol. 2016;22:382-389. [PMID: 27729633 DOI: 10.3350/cmh.2016.0047] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
363 Lai MW, Liang KH, Lin WR, Huang YH, Huang SF, Chen TC, Yeh CT. Hepatocarcinogenesis in transgenic mice carrying hepatitis B virus pre-S/S gene with the sW172* mutation. Oncogenesis 2016;5:e273. [PMID: 27918551 DOI: 10.1038/oncsis.2016.77] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
364 Zhu SL, Zhong JH, Ke Y, Xiao HM, Ma L, Chen J, You XM, Li LQ. Comparative efficacy of postoperative transarterial chemoembolization with or without antiviral therapy for hepatitis B virus-related hepatocellular carcinoma. Tumour Biol 2015;36:6277-84. [PMID: 25794642 DOI: 10.1007/s13277-015-3313-6] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
365 Villanueva A, Llovet JM. Targeted therapies for hepatocellular carcinoma. Gastroenterology 2011;140:1410-26. [PMID: 21406195 DOI: 10.1053/j.gastro.2011.03.006] [Cited by in Crossref: 310] [Cited by in F6Publishing: 310] [Article Influence: 31.0] [Reference Citation Analysis]
366 Seto WK, Yuen MF, Fung J, Lai CL. Tenofovir disoproxil fumarate for the treatment of chronic hepatitis B monoinfection. Hepatol Int 2013;7:327-34. [PMID: 21688182 DOI: 10.1007/s12072-011-9282-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
367 Murata M, Furusyo N, Unno M, Ogawa E, Toyoda K, Taniai H, Ohnishi H, Hayashi J. Long-term effects of lamivudine treatment in Japanese chronic hepatitis B patients. World J Gastroenterol 2011; 17(24): 2945-2952 [PMID: 21734806 DOI: 10.3748/wjg.v17.i24.2945] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
368 Kim MN, Hwang SG, Kim BK, Park JY, Kim DY, Han KH, Kim SU, Ahn SH. Liver Cirrhosis, Not Antiviral Therapy, Predicts Clinical Outcome in Cohorts with Heterogeneous Hepatitis B Viral Status. Gut Liver 2019;13:197-205. [PMID: 30602075 DOI: 10.5009/gnl18204] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
369 Russo FP, Rodríguez-Castro K, Scribano L, Gottardo G, Vanin V, Farinati F. Role of antiviral therapy in the natural history of hepatitis B virus-related chronic liver disease. World J Hepatol 2015; 7(8): 1097-1104 [PMID: 26052398 DOI: 10.4254/wjh.v7.i8.1097] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
370 Kaneko S, Kurosaki M, Joko K, Marusawa H, Kondo M, Kojima Y, Uchida Y, Kimura H, Tsuji K, Yagisawa H, Kusakabe A, Kobashi H, Akahane T, Tamaki N, Kirino S, Abe T, Yoshida H, Matsushita T, Hasebe C, Izumi N. Detectable HBV DNA during nucleos(t)ide analogues stratifies predictive hepatocellular carcinoma risk score. Sci Rep. 2020;10:13021. [PMID: 32747646 DOI: 10.1038/s41598-020-69522-w] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
371 Lee SB, Jeong J, Park JH, Jung SW, Jeong ID, Bang SJ, Shin JW, Park BR, Park EJ, Park NH. Low-level viremia and cirrhotic complications in patients with chronic hepatitis B according to adherence to entecavir. Clin Mol Hepatol 2020;26:364-75. [PMID: 32466635 DOI: 10.3350/cmh.2020.0012] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 8.0] [Reference Citation Analysis]
372 Akyildiz M, Gunsar F, Ersoz G, Karasu Z, Ilter T, Batur Y, Akarca U. Adefovir dipivoxil alone or in combination with lamivudine for three months in patients with lamivudine resistant compensated chronic hepatitis B. Dig Dis Sci. 2007;52:3444-3447. [PMID: 17431777 DOI: 10.1007/s10620-006-9718-8] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.0] [Reference Citation Analysis]
373 Sonneveld MJ, Janssen HL. Pros and Cons of Peginterferon Versus Nucleos(t)ide Analogues for Treatment of Chronic Hepatitis B. Curr Hepat Rep. 2010;9:91-98. [PMID: 20461129 DOI: 10.1007/s11901-010-0041-7] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 1.9] [Reference Citation Analysis]
374 Bailey MB, Shiau R, Zola J, Fernyak SE, Fang T, So SK, Chang ET. San Francisco hep B free: a grassroots community coalition to prevent hepatitis B and liver cancer. J Community Health 2011;36:538-51. [PMID: 21125320 DOI: 10.1007/s10900-010-9339-1] [Cited by in Crossref: 41] [Cited by in F6Publishing: 37] [Article Influence: 4.1] [Reference Citation Analysis]
375 El-Serag HB, Kanwal F. Epidemiology of hepatocellular carcinoma in the United States: where are we? Where do we go? Hepatology. 2014;60:1767-1775. [PMID: 24839253 DOI: 10.1002/hep.27222] [Cited by in Crossref: 380] [Cited by in F6Publishing: 355] [Article Influence: 54.3] [Reference Citation Analysis]
376 Tantai N, Chaikledkaew U, Tanwandee T, Werayingyong P, Teerawattananon Y. A cost-utility analysis of drug treatments in patients with HBeAg-positive chronic hepatitis B in Thailand. BMC Health Serv Res 2014;14:170. [PMID: 24731689 DOI: 10.1186/1472-6963-14-170] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
377 Kobayashi T, Ishiyama K, Ohdan H. Prevention of recurrence after curative treatment for hepatocellular carcinoma. Surg Today 2013;43:1347-54. [DOI: 10.1007/s00595-012-0473-5] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 1.6] [Reference Citation Analysis]
378 Kim AK, Singal AG. Health disparities in diagnosis and treatment of hepatocellular carcinoma. Clin Liver Dis (Hoboken) 2014;4:143-5. [PMID: 30992943 DOI: 10.1002/cld.427] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
379 Becker JC, Domschke W, Pohle T. [Medicinal prevention of gastrointestinal tumors: aspirin, Helicobacter and more?]. Internist (Berl) 2006;47:1229-30, 1232-4, 1236-8. [PMID: 17075707 DOI: 10.1007/s00108-006-1731-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
380 Honda K, Seike M, Murakami K. Benefits of nucleos(t)ide analog treatments for hepatitis B virus-related cirrhosis. World J Hepatol 2015; 7(22): 2404-2410 [PMID: 26464756 DOI: 10.4254/wjh.v7.i22.2404] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
381 Al-hamoudi W, Elsiesy H, Bendahmash A, Al-masri N, Ali S, Allam N, Al Sofayan M, Al Bahili H, Al Sebayel M, Broering D, Saab S, Abaalkhail F. Liver transplantation for hepatitis B virus: Decreasing indication and changing trends. World J Gastroenterol 2015; 21(26): 8140-8147 [PMID: 26185387 DOI: 10.3748/wjg.v21.i26.8140] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
382 Kim DY, Kim SU, Ahn SH, Park JY, Lee JM, Park YN, Yoon KT, Paik YH, Lee KS, Chon CY, Han KH. Usefulness of FibroScan for detection of early compensated liver cirrhosis in chronic hepatitis B. Dig Dis Sci. 2009;54:1758-1763. [PMID: 19005758 DOI: 10.1007/s10620-008-0541-2] [Cited by in Crossref: 90] [Cited by in F6Publishing: 101] [Article Influence: 6.9] [Reference Citation Analysis]
383 Le PH, Liang KH, Chang ML, Hsu CW, Chen YC, Lin CL, Lin WR, Lai MW, Yeh CT. Clinical Predictors for Neutrophil-to-Lymphocyte Ratio Changes in Patients with Chronic Hepatitis B Receiving Peginterferon Treatment. In Vivo. 2017;31:723-729. [PMID: 28652447 DOI: 10.21873/invivo.11121] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
384 Lim JH, Yu JH, Suh YJ, Lee JW, Jin YJ. Association between HBs Ag quantification and the risk of hepatocellular carcinoma in patients treated with tenofovir disoproxil fumarate or entecavir. Medicine (Baltimore) 2021;100:e27417. [PMID: 34596169 DOI: 10.1097/MD.0000000000027417] [Reference Citation Analysis]
385 Zhang M, Ge G, Yang Y, Cai X, Fu Q, Cai J, Huang Z. Decreased antigenicity profiles of immune-escaped and drug-resistant hepatitis B surface antigen (HBsAg) double mutants. Virol J 2013;10:292. [PMID: 24053482 DOI: 10.1186/1743-422X-10-292] [Cited by in Crossref: 15] [Cited by in F6Publishing: 8] [Article Influence: 1.9] [Reference Citation Analysis]
386 Rokuhara A, Matsumoto A, Tanaka E, Umemura T, Yoshizawa K, Kimura T, Maki N, Kiyosawa K. Hepatitis B virus RNA is measurable in serum and can be a new marker for monitoring lamivudine therapy. J Gastroenterol. 2006;41:785-790. [PMID: 16988768 DOI: 10.1007/s00535-006-1856-4] [Cited by in Crossref: 50] [Cited by in F6Publishing: 48] [Article Influence: 3.3] [Reference Citation Analysis]
387 Son SH, Kay CS, Song JH, Lee SW, Choi BO, Kang YN, Jang JW, Yoon SK, Jang HS. Dosimetric parameter predicting the deterioration of hepatic function after helical tomotherapy in patients with unresectable locally advanced hepatocellular carcinoma. Radiat Oncol 2013;8:11. [PMID: 23298438 DOI: 10.1186/1748-717X-8-11] [Cited by in Crossref: 16] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
388 Cassino L, Benetti S, Fay F, Tanno H, Quarleri J. Unsuccessful therapy with adefovir and entecavir-tenofovir in a patient with chronic hepatitis B infection with previous resistance to lamivudine: a fourteen-year evolution of hepatitis B virus mutations. BMC Infect Dis 2011;11:178. [PMID: 21696601 DOI: 10.1186/1471-2334-11-178] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
389 Kim BK, Kim SU, Kim HS, Park JY, Ahn SH, Chon CY, Cho IR, Joh DH, Park YN, Han KH, Kim DY. Prospective validation of FibroTest in comparison with liver stiffness for predicting liver fibrosis in Asian subjects with chronic hepatitis B. PLoS One. 2012;7:e35825. [PMID: 22536445 DOI: 10.1371/journal.pone.0035825] [Cited by in Crossref: 37] [Cited by in F6Publishing: 44] [Article Influence: 4.1] [Reference Citation Analysis]
390 Mealing S, Ghement I, Hawkins N, Scott DA, Lescrauwaet B, Watt M, Thursz M, Lampertico P, Mantovani L, Morais E, Bregman B, Cucherat M. The importance of baseline viral load when assessing relative efficacy in treatment-naïve HBeAg-positive chronic hepatitis B: a systematic review and network meta-analysis. Syst Rev 2014;3:21. [PMID: 24602249 DOI: 10.1186/2046-4053-3-21] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
391 Lee HW, Ahn SH. Prediction models of hepatocellular carcinoma development in chronic hepatitis B patients. World J Gastroenterol 2016; 22(37): 8314-8321 [PMID: 27729738 DOI: 10.3748/wjg.v22.i37.8314] [Cited by in CrossRef: 31] [Cited by in F6Publishing: 29] [Article Influence: 6.2] [Reference Citation Analysis]
392 Lin MT, Yen YH, Tsai MC, Tseng PL, Chang KC, Wu CK, Hu TH. Comparison of the Efficacies and Safety of Combined Therapy between Telbivudine Plus Adefovir and Lamivudine Plus Adefovir in Patients with Hepatitis B Virus Infection in Real-World Practice. PLoS One 2016;11:e0165416. [PMID: 27806120 DOI: 10.1371/journal.pone.0165416] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
393 Baumert TF, Thimme R, Weizsäcker FV. Pathogenesis of hepatitis B virus infection. World J Gastroenterol 2007; 13(1): 82-90 [PMID: 17206757 DOI: 10.3748/wjg.v13.i1.82] [Cited by in CrossRef: 90] [Cited by in F6Publishing: 79] [Article Influence: 6.4] [Reference Citation Analysis]
394 Ng J, Wu J. Hepatitis B- and hepatitis C-related hepatocellular carcinomas in the United States: similarities and differences. Hepat Mon 2012;12:e7635. [PMID: 23233865 DOI: 10.5812/hepatmon.7635] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 3.6] [Reference Citation Analysis]
395 Tong MJ, Pan CQ, Han SB, Lu DS, Raman S, Hu KQ, Lim JK, Hann HW, Min AD. An expert consensus for the management of chronic hepatitis B in Asian Americans. Aliment Pharmacol Ther 2018;47:1181-200. [PMID: 29479728 DOI: 10.1111/apt.14577] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 7.0] [Reference Citation Analysis]
396 Kim JH, Park YK, Park ES, Kim KH. Molecular diagnosis and treatment of drug-resistant hepatitis B virus. World J Gastroenterol 2014; 20(19): 5708-5720 [PMID: 24914332 DOI: 10.3748/wjg.v20.i19.5708] [Cited by in CrossRef: 27] [Cited by in F6Publishing: 19] [Article Influence: 3.9] [Reference Citation Analysis]
397 Kim DH, Kang HS, Hur SS, Sim S, Ahn SH, Park YK, Park ES, Lee AR, Park S, Kwon SY, Lee JH, Kim KH. Direct Detection of Drug-Resistant Hepatitis B Virus in Serum Using a Dendron-Modified Microarray. Gut Liver 2018;12:331-41. [PMID: 29271185 DOI: 10.5009/gnl17336] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
398 Liao B, Wang Z, Lin S, Xu Y, Yi J, Xu M, Huang Z, Zhou Y, Zhang F, Hou J. Significant fibrosis is not rare in Chinese chronic hepatitis B patients with persistent normal ALT. PLoS One 2013;8:e78672. [PMID: 24205292 DOI: 10.1371/journal.pone.0078672] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 3.4] [Reference Citation Analysis]
399 Ge GH, Ye Y, Zhou XB, Chen L, He C, Wen DF, Tan YW. Hepatitis B surface antigen levels of cessation of nucleos(t)ide analogs associated with virological relapse in hepatitis B surface antigen-negative chronic hepatitis B patients. World J Gastroenterol 2015; 21(28): 8653-8659 [PMID: 26229407 DOI: 10.3748/wjg.v21.i28.8653] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
400 Lemoine M, Nayagam S, Thursz M. Viral hepatitis in resource-limited countries and access to antiviral therapies: current and future challenges. Future Virol. 2013;8:371-380. [PMID: 23662157 DOI: 10.2217/fvl.13.11] [Cited by in Crossref: 77] [Cited by in F6Publishing: 64] [Article Influence: 9.6] [Reference Citation Analysis]
401 Yim HJ, Kim JH, Park JY, Yoon EL, Park H, Kwon JH, Sinn DH, Lee SH, Lee JH, Lee HW. Comparison of clinical practice guidelines for the management of chronic hepatitis B: When to start, when to change, and when to stop. Clin Mol Hepatol. 2020;26:411-429. [PMID: 32854458 DOI: 10.3350/cmh.2020.0049] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 10.0] [Reference Citation Analysis]
402 Shin JW, Park NH, Jung SW, Kim BC, Kwon SH, Park JS, Jeong ID, Bang SJ, Kim DH. Clinical significance of hepatitis B e antigen level easurement during long-term lamivudine therapy in chronic hepatitis B patients with e antigen positive. World J Gastroenterol 2006; 12(41): 6693-6698 [PMID: 17075986 DOI: 10.3748/wjg.v12.i41.6693] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
403 Azmi AN, Tan SS, Mohamed R. Practical approach in hepatitis B e antigen-negative individuals to identify treatment candidates. World J Gastroenterol 2014; 20(34): 12045-12055 [PMID: 25232242 DOI: 10.3748/wjg.v20.i34.12045] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
404 Ko SY, Kim BK, Kwon SY, Kim KH, Kim JH, Choe WH, Lee CH. Clonal evolution of hepatitis B virus polymerase gene mutations during lamivudine-adefovir combination treatment. World J Gastroenterol 2012; 18(44): 6437-6446 [PMID: 23197889 DOI: 10.3748/wjg.v18.i44.6437] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
405 Goto T, Yoshida H, Tateishi R, Enooku K, Goto E, Sato T, Ohki T, Masuzaki R, Imamura J, Shiina S. Influence of serum HBV DNA load on recurrence of hepatocellular carcinoma after treatment with percutaneous radiofrequency ablation. Hepatol Int. 2011;5:767-773. [PMID: 21484129 DOI: 10.1007/s12072-011-9255-1] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 2.1] [Reference Citation Analysis]
406 Luetkemeyer AF, Charlebois ED, Hare CB, Black D, Smith A, Havlir DV, Peters MG. Resistance patterns and response to entecavir intensification among HIV-HBV-coinfected adults with persistent HBV viremia. J Acquir Immune Defic Syndr 2011;58:e96-9. [PMID: 22005002 DOI: 10.1097/QAI.0b013e3182303937] [Cited by in Crossref: 3] [Article Influence: 0.3] [Reference Citation Analysis]
407 El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology. 2012;142:1264-1273.e1. [PMID: 22537432 DOI: 1053/j.gastro.2011.12.061] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
408 Khalili M, Guy J, Yu A, Li A, Diamond-Smith N, Stewart S, Chen M Jr, Nguyen T. Hepatitis B and hepatocellular carcinoma screening among Asian Americans: survey of safety net healthcare providers. Dig Dis Sci. 2011;56:1516-1523. [PMID: 21046247 DOI: 10.1007/s10620-010-1439-3] [Cited by in Crossref: 41] [Cited by in F6Publishing: 40] [Article Influence: 3.7] [Reference Citation Analysis]
409 Tsai MC, Chen YT, Chien YS, Chen TC, Hu TH. Hepatitis B virus infection and renal transplantation. World J Gastroenterol 2010; 16(31): 3878-3887 [PMID: 20712048 DOI: 10.3748/wjg.v16.i31.3878] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
410 Chung KH, Kim W, Kim BG, Lee HY, Jin E, Cho Y, Seo JY, Kim HY, Jung YJ, Kim JW, Jeong JB, Lee KL. Hepatitis B Surface Antigen Quantification across Different Phases of Chronic Hepatitis B Virus Infection Using an Immunoradiometric Assay. Gut Liver. 2015;9:657-664. [PMID: 25717049 DOI: 10.5009/gnl14188] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.4] [Reference Citation Analysis]
411 Magoro T, Gachara G, Mavhandu L, Lum E, Kimbi HK, Ndip RN, Bessong P. Serologic and genotypic characterization of hepatitis B virus in HIV-1 infected patients from South West and Littoral Regions of Cameroon. Virol J 2016;13:178. [PMID: 27769271 DOI: 10.1186/s12985-016-0636-x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
412 Shin SR, Koh KC, Gwak GY, Choi MS, Lee JH, Paik SW, Yoo BC. A low viral load predicts a higher initial virologic response to adefovir in patients with Lamivudine-resistant chronic hepatitis B. J Gut Liver. 2010;4:530-536. [PMID: 21253304 DOI: 10.5009/gnl.2010.4.4.530] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
413 Seo YS, Kim MN, Kim SU, Kim SG, Um SH, Han KH, Kim YS. Risk Assessment of Hepatocellular Carcinoma Using Transient Elastography Vs. Liver Biopsy in Chronic Hepatitis B Patients Receiving Antiviral Therapy. Medicine (Baltimore). 2016;95:e2985. [PMID: 27015173 DOI: 10.1097/md.0000000000002985] [Cited by in Crossref: 15] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
414 Tan ZM, Sun BC. Effects of antiviral therapy on preventing liver tumorigenesis and hepatocellular carcinoma recurrence. World J Gastroenterol 2013; 19(47): 8895-8901 [PMID: 24379613 DOI: 10.3748/wjg.v19.i47.8895] [Cited by in CrossRef: 20] [Cited by in F6Publishing: 19] [Article Influence: 2.5] [Reference Citation Analysis]
415 Suzuki F, Arase Y, Suzuki Y, Akuta N, Sezaki H, Seko Y, Kawamura Y, Hosaka T, Kobayashi M, Saito S. Long-term efficacy of interferon therapy in patients with chronic hepatitis B virus infection in Japan. J Gastroenterol. 2012; Feb 24. [Epub ahead of print]. [PMID: 22361865 DOI: 10.1007/s00535-012-0548-5] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 1.7] [Reference Citation Analysis]
416 Di Bisceglie AM. Hepatitis B and hepatocellular carcinoma. Hepatology 2009;49:S56-60. [PMID: 19399807 DOI: 10.1002/hep.22962] [Cited by in Crossref: 195] [Cited by in F6Publishing: 175] [Article Influence: 16.3] [Reference Citation Analysis]
417 Changchien CS, Chen CL, Yen YH, Wang JH, Hu TH, Lee CM, Wang CC, Cheng YF, Huang YJ, Lin CY. Analysis of 6381 hepatocellular carcinoma patients in southern Taiwan: prognostic features, treatment outcome, and survival. J Gastroenterol. 2008;43:159-170. [PMID: 18306990 DOI: 10.1007/s00535-007-2134-9] [Cited by in Crossref: 45] [Cited by in F6Publishing: 46] [Article Influence: 3.5] [Reference Citation Analysis]
418 Fong TL, Tien A, Jo KJ, Chu D, Cheung E, Mena EA, Phan QQ, Yu AS, Mohammed W, Velasco A. Durability of Hepatitis B e Antigen Seroconversion in Chronic Hepatitis B Patients Treated with Entecavir or Tenofovir. Dig Dis Sci. 2015;60:3465-3472. [PMID: 26138653 DOI: 10.1007/s10620-015-3775-9] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 2.5] [Reference Citation Analysis]
419 Sohn W, Kang TW, Choi SK, Jung SH, Lee MW, Lim HK, Cho JY, Shim SG, Sinn DH, Gwak GY, Choi MS, Lee JH, Koh KC, Paik SW, Rhim H, Paik YH. Effect of oral antiviral treatment on long-term outcomes of radiofrequency ablation therapy for hepatitis B virus-related hepatocellular carcinoma. Oncotarget 2016;7:47794-807. [PMID: 27329596 DOI: 10.18632/oncotarget.10026] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
420 Thiele M, Gluud LL, Dahl EK, Krag A. Antiviral therapy for prevention of hepatocellular carcinoma and mortality in chronic hepatitis B: systematic review and meta-analysis. BMJ Open 2013;3:e003265. [PMID: 23945731 DOI: 10.1136/bmjopen-2013-003265] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 2.5] [Reference Citation Analysis]
421 Waghray A, Murali AR, Menon KN. Hepatocellular carcinoma: From diagnosis to treatment. World J Hepatol 2015; 7(8): 1020-1029 [PMID: 26052391 DOI: 10.4254/wjh.v7.i8.1020] [Cited by in Crossref: 81] [Cited by in F6Publishing: 83] [Article Influence: 13.5] [Reference Citation Analysis]
422 Sherman M. Why adefovir is not yet available in Canada. Can J Gastroenterol 2006;20:694-6. [PMID: 17111050 DOI: 10.1155/2006/826093] [Reference Citation Analysis]
423 Kilickap S, Kars A, Hamaloglu E, Simsek H. A case of recurrent metastatic hepatocellular cancer controlled with immunotherapy and antiviral therapy following resection. Med Oncol 2009;26:501-5. [PMID: 19688614 DOI: 10.1007/s12032-008-9083-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
424 Chan HL, Wong VW, Wong GL, Chim AM, Lai LH, Sung JJ. Evaluation of impact of serial hepatitis B virus DNA levels on development of hepatocellular carcinoma. J Clin Microbiol 2009;47:1830-6. [PMID: 19386857 DOI: 10.1128/JCM.00029-09] [Cited by in Crossref: 15] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
425 Kwon H, Lok AS. Hepatitis B therapy. Nat Rev Gastroenterol Hepatol. 2011;8:275-284. [PMID: 21423260 DOI: 10.1038/nrgastro.2011.33] [Cited by in Crossref: 171] [Cited by in F6Publishing: 164] [Article Influence: 17.1] [Reference Citation Analysis]
426 Fazle Akbar SM, Al-Mahtab M, Hiasa Y. Designing immune therapy for chronic hepatitis B. J Clin Exp Hepatol. 2014;4:241-246. [PMID: 25755566 DOI: 10.1016/j.jceh.2014.06.008] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
427 Nguyen MH, Wong G, Gane E, Kao JH, Dusheiko G. Hepatitis B Virus: Advances in Prevention, Diagnosis, and Therapy. Clin Microbiol Rev. 2020;33. [PMID: 32102898 DOI: 10.1128/cmr.00046-19] [Cited by in Crossref: 37] [Cited by in F6Publishing: 18] [Article Influence: 37.0] [Reference Citation Analysis]
428 Yeh CT, Chen T, Hsu CW, Chen YC, Lai MW, Liang KH, Chen TC. Emergence of the rtA181T/sW172* mutant increased the risk of hepatoma occurrence in patients with lamivudine-resistant chronic hepatitis B. BMC Cancer. 2011;11:398. [PMID: 21933446 DOI: 10.1186/1471-2407-11-398] [Cited by in Crossref: 35] [Cited by in F6Publishing: 35] [Article Influence: 3.5] [Reference Citation Analysis]
429 Zoulim F. Hepatitis B virus resistance to antiviral drugs: where are we going? Liver Int. 2011;31 Suppl 1:111-116. [PMID: 21205147 DOI: 10.1111/j.1478-3231.2010.02399.x.] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
430 Kim JS, Hahn JS, Park SY, Kim Y, Park IH, Lee CK, Cheong JW, Lee ST, Min YH. Long-term outcome after prophylactic lamivudine treatment on hepatitis B virus reactivation in non-Hodgkin’s lymphoma. Yonsei Med J. 2007;48:78-89. [PMID: 17326249 DOI: 10.3349/ymj.2007.48.1.78] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]
431 Kanda T. No additive effects of peginterferon on the short-term improvement of liver histology by entecavir monotherapy in chronic hepatitis B patients. Hepatol Int 2021;15:579-81. [PMID: 33900575 DOI: 10.1007/s12072-021-10191-w] [Reference Citation Analysis]
432 Sano T, Kawaguchi T, Ide T, Amano K, Kuwahara R, Arinaga-Hino T, Torimura T. Tenofovir Alafenamide Rescues Renal Tubules in Patients with Chronic Hepatitis B. Life (Basel) 2021;11:263. [PMID: 33806752 DOI: 10.3390/life11030263] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
433 Lee YB, Lee JH, Choi WM, Cho YY, Yoo JJ, Lee M, Lee DH, Cho Y, Yu SJ, Kim YJ. Efficacy of adefovir-based combination therapy for patients with Lamivudine- and entecavir-resistant chronic hepatitis B virus infection. Antimicrob Agents Chemother. 2013;57:6325-6332. [PMID: 24100506 DOI: 10.1128/aac.01742-13aac.01742-13] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
434 Lee CI, Kwon SY, Kim JH, Choe WH, Lee CH, Yoon EL, Yeon JE, Byun KS, Kim YS, Kim JH. Efficacy and safety of tenofovir-based rescue therapy for chronic hepatitis B patients with previous nucleo(s/t)ide treatment failure. Gut Liver. 2014;8:64-69. [PMID: 24516703 DOI: 10.5009/gnl.2014.8.1.64] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
435 Blum HE. Hepatocellular carcinoma: therapy and prevention. World J Gastroenterol. 2005;11:7391-7400. [PMID: 16437707 DOI: 10.3748/wjg.v11.i47.7391] [Cited by in CrossRef: 36] [Cited by in F6Publishing: 94] [Article Influence: 2.4] [Reference Citation Analysis]
436 Tong GD, Zhang X, Zhou DQ, Wei CS, He JS, Xiao CL, Liu XL, Zheng YJ, Chen SN, Tang HH. Efficacy of early treatment on 52 patients with preneoplastic hepatitis B virus-associated hepatocellular carcinoma by compound Phyllanthus Urinaria L. Chin J Integr Med 2014;20:263-71. [PMID: 23529834 DOI: 10.1007/s11655-013-1320-7] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
437 Chen LP, Zhao J, Du Y, Han YF, Su T, Zhang HW, Cao GW. Antiviral treatment to prevent chronic hepatitis B or C-related hepatocellular carcinoma. World J Virol 2012; 1(6): 174-183 [PMID: 24175223 DOI: 10.5501/wjv.v1.i6.174] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 20] [Article Influence: 2.3] [Reference Citation Analysis]
438 Suk-Fong Lok A. Hepatitis B Treatment: What We Know Now and What Remains to Be Researched. Hepatol Commun. 2019;3:8-19. [PMID: 30619990 DOI: 10.1002/hep4.1281] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 8.0] [Reference Citation Analysis]
439 Chien RN. Current therapy for hepatitis C or D or immunodeficiency virus concurrent infection with chronic hepatitis B. Hepatol Int 2008;2:296-303. [PMID: 19669257 DOI: 10.1007/s12072-008-9066-1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
440 Hosaka T, Suzuki F, Suzuki Y, Saitoh S, Kobayashi M, Someya T, Sezaki H, Akuta N, Arase Y, Ikeda K, Kumada H. Factors associated with the virological response of lamivudine-resistant hepatitis B virus during combination therapy with adefovir dipivoxil plus lamivudine. J Gastroenterol 2007;42:368-74. [PMID: 17530361 DOI: 10.1007/s00535-007-2008-1] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
441 El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology. 2012;142:1264-1273.e1. [PMID: 22537432 DOI: 10.1053/j.gastro.2011.12] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
442 Kim JH, Lee JS. Is tenofovir disoproxil fumarate an all-powerful weapon in the treatment of chronic hepatitis B? Korean J Intern Med 2015;30:23-6. [PMID: 25589830 DOI: 10.3904/kjim.2015.30.1.23] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
443 Harris PS, Hansen RM, Gray ME, Massoud OI, McGuire BM, Shoreibah MG. Hepatocellular carcinoma surveillance: An evidence-based approach. World J Gastroenterol 2019; 25(13): 1550-1559 [PMID: 30983815 DOI: 10.3748/wjg.v25.i13.1550] [Cited by in CrossRef: 44] [Cited by in F6Publishing: 37] [Article Influence: 22.0] [Reference Citation Analysis]
444 Liu CL, Wu CK, Shi HY, Tai WC, Liang CM, Yang SC, Wu KL, Chiu YC, Chuah SK. Medical expenses in treating acute esophageal variceal bleeding: A 15-year nationwide population-based cohort study. Medicine (Baltimore) 2016;95:e4215. [PMID: 27428225 DOI: 10.1097/MD.0000000000004215] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.8] [Reference Citation Analysis]
445 Shi H, Lu L, Zhang NP, Zhang SC, Shen XZ. Effect of interferon-γ and tumor necrosis factor-α on hepatitis B virus following lamivudine treatment. World J Gastroenterol 2012; 18(27): 3617-3622 [PMID: 22826629 DOI: 10.3748/wjg.v18.i27.3617] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
446 Ye YA, Li XK, Zhou DQ, Chi XL, Li Q, Wang L, Lu BJ, Mao DW, Wu QK, Wang XB, Zhang MX, Xue JD, Li Y, Lu W, Guo JC, Jiang F, Zhang XW, Du HB, Yang XZ, Guo H, Gan DN, Li ZG. Chinese Herbal Medicine Combined with Entecavir for HBeAg Positive Chronic Hepatitis B: Study Protocol for a Multi-Center, Double-Blind Randomized-Controlled Trial. Chin J Integr Med 2018;24:653-60. [PMID: 30209792 DOI: 10.1007/s11655-018-3011-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
447 Yu SK, Kwon OS, Jung HS, Bae KS, Kwon KA, Kim YK, Kim YS, Kim JH. Influence of transforming growth factor-beta1 gene polymorphism at codon 10 on the development of cirrhosis in chronic hepatitis B virus carriers. J Korean Med Sci. 2010;25:564-569. [PMID: 20357999 DOI: 10.3346/jkms.2010.25.4.564] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
448 Tacke F, Kroy DC. Treatment for hepatitis B in patients with drug resistance. Ann Transl Med 2016;4:334. [PMID: 27761438 DOI: 10.21037/atm.2016.09.19] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.4] [Reference Citation Analysis]
449 Lee J, Sinn DH, Paik SW. The Author's Response: Anti-Viral Therapy for Compensated Liver Cirrhosis Patients with Normal Alanine Aminotransferase. J Korean Med Sci 2016;31:825-6. [PMID: 27134510 DOI: 10.3346/jkms.2016.31.5.825] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
450 Tarao K, Nozaki A, Ikeda T, Sato A, Komatsu H, Komatsu T, Taguri M, Tanaka K. Real impact of liver cirrhosis on the development of hepatocellular carcinoma in various liver diseases-meta-analytic assessment. Cancer Med 2019;8:1054-65. [PMID: 30791221 DOI: 10.1002/cam4.1998] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 9.5] [Reference Citation Analysis]
451 Lampertico P, Aghemo A, Viganò M, Colombo M. HBV and HCV therapy. Viruses 2009;1:484-509. [PMID: 21994557 DOI: 10.3390/v1030484] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
452 Su TH, Kao JH, Liu CJ. Molecular mechanism and treatment of viral hepatitis-related liver fibrosis. Int J Mol Sci. 2014;15:10578-10604. [PMID: 24927147 DOI: 10.3390/ijms150610578] [Cited by in Crossref: 44] [Cited by in F6Publishing: 42] [Article Influence: 6.3] [Reference Citation Analysis]
453 Lai MW, Liang KH, Yeh CT. Hepatitis B Virus preS/S Truncation Mutant rtM204I/sW196* Increases Carcinogenesis through Deregulated HIF1A, MGST2, and TGFbi. Int J Mol Sci 2020;21:E6366. [PMID: 32887289 DOI: 10.3390/ijms21176366] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
454 Welker MW, Zeuzem S. Pre- and Post-Transplant Antiviral Therapy (HBV, HCV). Visc Med 2016;32:105-9. [PMID: 27413727 DOI: 10.1159/000445152] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
455 Liu TT, Fang Y, Xiong H, Chen TY, Ni ZP, Luo JF, Zhao NQ, Shen XZ. A case-control study of the relationship between hepatitis B virus DNA level and risk of hepatocellular carcinoma in Qidong, China. World J Gastroenterol 2008; 14(19): 3059-3063 [PMID: 18494059 DOI: 10.3748/wjg.14.3059] [Cited by in CrossRef: 27] [Cited by in F6Publishing: 26] [Article Influence: 2.1] [Reference Citation Analysis]
456 Lu H, Geng da Y, Shen F, Zhang JY, Lu B, Ma LX. Optimization of adefovir therapy in chronic hepatitis B according to baseline predictors and on-treatment HBV DNA: a 5-year prospective study. Virol J 2011;8:444. [PMID: 21936898 DOI: 10.1186/1743-422X-8-444] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
457 Yao M, Wang L, Leung PSC, Li Y, Liu S, Wang L, Guo X, Zhou G, Yan Y, Guan G, Chen X, Bowlus CL, Liu T, Jia J, Gershwin ME, Ma X, Zhao J, Lu F. The Clinical Significance of GP73 in Immunologically Mediated Chronic Liver Diseases: Experimental Data and Literature Review. Clin Rev Allergy Immunol. 2018;54:282-294. [PMID: 29256057 DOI: 10.1007/s12016-017-8655-y] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 6.0] [Reference Citation Analysis]
458 Singal AG, Lampertico P, Nahon P. Epidemiology and surveillance for hepatocellular carcinoma: New trends. J Hepatol. 2020;72:250-261. [PMID: 31954490 DOI: 10.1016/j.jhep.2019.08.025] [Cited by in Crossref: 131] [Cited by in F6Publishing: 145] [Article Influence: 131.0] [Reference Citation Analysis]
459 Thylur RP, Roy SK, Shrivastava A, LaVeist TA, Shankar S, Srivastava RK. Assessment of risk factors, and racial and ethnic differences in hepatocellular carcinoma. JGH Open 2020;4:351-9. [PMID: 32514436 DOI: 10.1002/jgh3.12336] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
460 Grimm D, Thimme R, Blum HE. HBV life cycle and novel drug targets. Hepatol Int 2011;5:644-53. [PMID: 21484123 DOI: 10.1007/s12072-011-9261-3] [Cited by in Crossref: 72] [Cited by in F6Publishing: 71] [Article Influence: 7.2] [Reference Citation Analysis]
461 Sacco R. Update on entecavir in the management of severe forms of Hepatitis B. Hepat Med 2012;4:39-47. [PMID: 24696620 DOI: 10.2147/HMER.S16136] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
462 Yamada R, Hiramatsu N, Oze T, Morishita N, Harada N, Yakushijin T, Iio S, Doi Y, Yamada A, Kaneko A. Impact of alpha-fetoprotein on hepatocellular carcinoma development during entecavir treatment of chronic hepatitis B virus infection. J Gastroenterol. 2015;50:785-794. [PMID: 25384794 DOI: 10.1007/s00535-014-1010-7] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 2.9] [Reference Citation Analysis]
463 Yip TC, Lai JC, Wong GL. Secondary prevention for hepatocellular carcinoma in patients with chronic hepatitis B: are all the nucleos(t)ide analogues the same? J Gastroenterol 2020;55:1023-36. [PMID: 32974760 DOI: 10.1007/s00535-020-01726-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
464 Haering C, McMahon B, Harris A, Weis N, Lundberg Ederth J, Axelsson M, Olafsson S, Osiowy C, Tomas K, Bollerup S, Liitsola K, Archibald C, Blystad H, Bruce M, Nolen L. Hepatitis B virus elimination status and strategies in circumpolar countries, 2020. Int J Circumpolar Health 2021;80:1986975. [PMID: 34668463 DOI: 10.1080/22423982.2021.1986975] [Reference Citation Analysis]
465 Zoulim F, Poynard T, Degos F, Slama A, El Hasnaoui A, Blin P, Mercier F, Deny P, Landais P, Parvaz P, Trepo C; Lamivir Study Group. A prospective study of the evolution of lamivudine resistance mutations in patients with chronic hepatitis B treated with lamivudine. J Viral Hepat. 2006;13:278-288. [PMID: 16611195 DOI: 10.1111/j.1365-2893.2005.00712.x] [Cited by in Crossref: 54] [Cited by in F6Publishing: 49] [Article Influence: 3.6] [Reference Citation Analysis]
466 Alam S, Azam G, Mustafa G, Ahmad N, Islam B, Podder PK, Khan M. Pretreatment and on-treatment predictors of viral breakthrough in lamivudine therapy for chronic hepatitis B. Hepatol Int 2008;2:494-7. [PMID: 19669325 DOI: 10.1007/s12072-008-9095-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
467 Bowden S, Locarnini S, Chang TT, Chao YC, Han KH, Gish RG, de Man RA, Yu M, Llamoso C, Tang H. Covalently closed-circular hepatitis B virus DNA reduction with entecavir or lamivudine. World J Gastroenterol 2015; 21(15): 4644-4651 [PMID: 25914474 DOI: 10.3748/wjg.v21.i15.4644] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.7] [Reference Citation Analysis]
468 Kuo MJ, Chen HH, Chen CL, Fann JCY, Chen SLS, Chiu SYH, Lin YM, Liao CS, Chang HC, Lin YS, Yen AMF. Cost-effectiveness analysis of population-based screening of hepatocellular carcinoma: Comparing ultrasonography with two-stage screening. World J Gastroenterol 2016; 22(12): 3460-3470 [PMID: 27022228 DOI: 10.3748/wjg.v22.i12.3460] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
469 Fujii H, Yamaguchi S, Kurai O, Miyano M, Ueda W, Oba H, Aoki T, Enomoto M, Kawada N, Okawa K. Putting "sticky notes" on the electronic medical record to promote intra-hospital referral of hepatitis B and C virus-positive patients to hepatology specialists: an exploratory study. BMC Infect Dis 2016;16:410. [PMID: 27519695 DOI: 10.1186/s12879-016-1765-y] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]
470 Lee CH, Kim IH, Moon JC, Seo SY, Kim SH, Kim SW, Lee SO, Lee ST, Kim DG, Yang JD, Yu HC. 3-Dimensional liver volume assessment in patients with hepatitis B virus-related liver cirrhosis during long-term oral nucleos(t)ide analogues therapy. World J Gastroenterol 2017; 23(2): 297-305 [PMID: 28127203 DOI: 10.3748/wjg.v23.i2.297] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
471 Abu-Freha N, Abu Tailakh M, Fich A, Abu Bader N, Shemer-Avni Y, Alsana F, Gasper N, Abu-Kaf H, Etzion O. Adherence to Anti-Viral Treatment for Chronic Hepatitis B. J Clin Med 2020;9:E1922. [PMID: 32575498 DOI: 10.3390/jcm9061922] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
472 Bashir Hamidu R, Chalikonda DM, Hann HW. Gender Disparity in Host Responses to Hepatitis B-Related Hepatocellular Carcinoma: A Case Series. Vaccines (Basel) 2021;9:838. [PMID: 34451963 DOI: 10.3390/vaccines9080838] [Reference Citation Analysis]
473 Son SH, Jang HS, Lee H, Choi BO, Kang YN, Jang JW, Yoon SK, Kay CS. Determination of the α/β ratio for the normal liver on the basis of radiation-induced hepatic toxicities in patients with hepatocellular carcinoma. Radiat Oncol 2013;8:61. [PMID: 23497395 DOI: 10.1186/1748-717X-8-61] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
474 Yeh YC, Liu CJ, Kuo RN, Lai CL, Shau WY, Chen PJ, Lai MS. Association of adjuvant antiviral therapy with risk of cancer progression and deaths in patients with hepatitis-B-virus-related hepatocellular carcinoma following curative treatment: a nationwide cohort study. PLoS One. 2014;9:e102051. [PMID: 25025231 DOI: 10.1371/journal.pone.0102051] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
475 Yoo J, Hann HW, Coben R, Conn M, DiMarino AJ. Update Treatment for HBV Infection and Persistent Risk for Hepatocellular Carcinoma: Prospect for an HBV Cure. Diseases. 2018;6:E27. [PMID: 29677098 DOI: 10.3390/diseases6020027] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 4.3] [Reference Citation Analysis]
476 Yildiz UH, Inci F, Wang S, Toy M, Tekin HC, Javaid A, Lau DT, Demirci U. Recent advances in micro/nanotechnologies for global control of hepatitis B infection. Biotechnol Adv 2015;33:178-90. [PMID: 25450190 DOI: 10.1016/j.biotechadv.2014.11.003] [Cited by in Crossref: 30] [Cited by in F6Publishing: 24] [Article Influence: 4.3] [Reference Citation Analysis]
477 Vitor S, Marinho RT, Gíria J, Velosa J. An observational study of the direct costs related to hospital admissions, mortality and premature death associated with liver disease in Portugal. BMC Res Notes 2016;9:62. [PMID: 26843372 DOI: 10.1186/s13104-016-1879-8] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
478 Song ZL, Cui YJ, Zheng WP, Teng DH, Zheng H. Application of nucleoside analogues to liver transplant recipients with hepatitis B. World J Gastroenterol 2015; 21(42): 12091-12100 [PMID: 26576094 DOI: 10.3748/wjg.v21.i42.12091] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
479 Murata K, Asano M, Matsumoto A, Sugiyama M, Nishida N, Tanaka E, Inoue T, Sakamoto M, Enomoto N, Shirasaki T, Honda M, Kaneko S, Gatanaga H, Oka S, Kawamura YI, Dohi T, Shuno Y, Yano H, Mizokami M. Induction of IFN-λ3 as an additional effect of nucleotide, not nucleoside, analogues: a new potential target for HBV infection. Gut 2018;67:362-71. [PMID: 27789659 DOI: 10.1136/gutjnl-2016-312653] [Cited by in Crossref: 76] [Cited by in F6Publishing: 68] [Article Influence: 15.2] [Reference Citation Analysis]
480 TrehanPati N, Kotillil S, Hissar SS, Shrivastava S, Khanam A, Sukriti S, Mishra SK, Sarin SK. Circulating Tregs correlate with viral load reduction in chronic HBV-treated patients with tenofovir disoproxil fumarate. J Clin Immunol. 2011;31:509-520. [PMID: 21305387 DOI: 10.1007/s10875-011-9509-7] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 2.5] [Reference Citation Analysis]
481 El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology. 2012;142:1264-1273.e1. [PMID: 22537432 DOI: 10.1053/j.gastro.2011.12.061] [Cited by in Crossref: 1846] [Cited by in F6Publishing: 1795] [Article Influence: 205.1] [Reference Citation Analysis]
482 Ding R, Zheng J, Huang D, Wang Y, Li X, Zhou X, Yan L, Lu W, Yang Z, Zhang Z. INR-to-platelet ratio (INPR) as a novel noninvasive index for predicting liver fibrosis in chronic hepatitis B. Int J Med Sci 2021;18:1159-66. [PMID: 33526976 DOI: 10.7150/ijms.51799] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
483 Yang JD, Roberts LR. Hepatocellular carcinoma: A global view. Nat Rev Gastroenterol Hepatol 2010;7:448-58. [PMID: 20628345 DOI: 10.1038/nrgastro.2010.100] [Cited by in Crossref: 810] [Cited by in F6Publishing: 813] [Article Influence: 73.6] [Reference Citation Analysis]
484 Cattamanchi A, Saracino M, Selke S, Huang ML, Magaret A, Celum C, Corey L, Wald A, Casper C. Treatment with valacyclovir, famciclovir, or antiretrovirals reduces human herpesvirus-8 replication in HIV-1 seropositive men. J Med Virol 2011;83:1696-703. [PMID: 21837785 DOI: 10.1002/jmv.22194] [Cited by in Crossref: 17] [Cited by in F6Publishing: 10] [Article Influence: 1.9] [Reference Citation Analysis]
485 Lee YB, Lee JH, Choi WM, Cho YY, Yoo JJ, Lee M, Lee DH, Cho Y, Yu SJ, Kim YJ, Yoon JH, Kim CY, Lee HS. Efficacy of adefovir-based combination therapy for patients with Lamivudine- and entecavir-resistant chronic hepatitis B virus infection. Antimicrob Agents Chemother 2013;57:6325-32. [PMID: 24100506 DOI: 10.1128/AAC.01742-13] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
486 Colombo M, Lleo A. The impact of antiviral therapy on hepatocellular carcinoma epidemiology. Hepat Oncol 2018;5:HEP03. [PMID: 30302194 DOI: 10.2217/hep-2017-0024] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 3.7] [Reference Citation Analysis]
487 Zhang QQ, An X, Liu YH, Li SY, Zhong Q, Wang J, Hu HD, Zhang DZ, Ren H, Hu P. Long-term nucleos(t)ide analogues therapy for adults with chronic hepatitis B reduces the risk of long-term complications: a meta-analysis. Virol J. 2011;8:72. [PMID: 21324130 DOI: 10.1186/1743-422x-8-72] [Cited by in Crossref: 42] [Cited by in F6Publishing: 18] [Article Influence: 4.2] [Reference Citation Analysis]
488 Rahimi R, Hosseini SY, Fattahi MR, Sepehrimanesh M, Safarpour A, Malekhosseini SA, Nejabat M, Khodadad M, Ardebili M. YMDD Motif Mutation Profile Among Patients Receiving Liver Transplant Due to Hepatitis B Virus Infection With Long Term Lamivudine/Immunoglobulin Therapy. Hepat Mon 2015;15:e27120. [PMID: 26300928 DOI: 10.5812/hepatmon.27120v2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
489 Zoulim F. Emerging drugs for hepatitis B. Expert Opin Emerg Drugs 2007;12:199-217. [PMID: 17604497 DOI: 10.1517/14728214.12.2.199] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 0.7] [Reference Citation Analysis]
490 Cholongitas E, Papatheodoridis GV. Review of the pharmacological management of hepatitis B viral infection before and after liver transplantation. World J Gastroenterol 2013; 19(48): 9189-9197 [PMID: 24409047 DOI: 10.3748/wjg.v19.i48.9189] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 19] [Article Influence: 2.6] [Reference Citation Analysis]
491 Shan X, Liu S, Liu J, Zhu H, Xiao Y, Chen Y. Geographical survey of the intermediate host of Schistosoma japonicum: Toward precise management of Oncomelania hupensis. PLoS Negl Trop Dis 2020;14:e0008674. [PMID: 33027249 DOI: 10.1371/journal.pntd.0008674] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
492 Hidaka I, Enomoto M, Sato S, Suetsugu A, Matono T, Ito K, Ogawa K, Inoue J, Horino M, Kondo Y, Sakaida I, Korenaga M. Establishing Efficient Systems through Electronic Medical Records to Promote Intra-hospital Referrals of Hepatitis Virus Carriers to Hepatology Specialists: A Multicenter Questionnaire-based Survey of 1,281 Healthcare Professionals. Intern Med 2021;60:337-43. [PMID: 33518608 DOI: 10.2169/internalmedicine.4748-20] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
493 Yoshida H, Yoshida H, Goto E, Sato T, Ohki T, Masuzaki R, Tateishi R, Goto T, Shiina S, Kawabe T. Safety and efficacy of lamivudine after radiofrequency ablation in patients with hepatitis B virus-related hepatocellular carcinoma. Hepatol Int. 2008;2:89-94. [PMID: 19669283 DOI: 10.1007/s12072-007-9020-7] [Cited by in Crossref: 38] [Cited by in F6Publishing: 35] [Article Influence: 2.7] [Reference Citation Analysis]
494 Lee HW, Park JY, Kim BK, Kim MY, Lee JI, Kim YS, Yoon KT, Han KH, Ahn SH. Efficacy of switching from adefovir to tenofovir in chronic hepatitis B patients who exhibit suboptimal responses to adefovir-based combination rescue therapy due to resistance to nucleoside analogues (SATIS study). Clin Mol Hepatol 2016;22:443-9. [PMID: 27880997 DOI: 10.3350/cmh.2016.0037] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
495 Liang KH, Chen YC, Hsu CW, Chang ML, Yeh CT. Decrease of serum Angiotensin converting enzyme levels upon telbivudine treatment for chronic hepatitis B virus infection and negative correlations between the enzyme levels and estimated glumerular filtration rates. Hepat Mon. 2014;14:e15074. [PMID: 24596580 DOI: 10.5812/hepatmon.15074] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
496 Lim JK, Chang AY, Zaman A, Martin P, Fernandez-Rodriguez CM, Korkmaz M, Rossi S, Ford JM, Noonan T, Cooney E, Navarro V, Colombato L. Clinical Outcome Event Adjudication in a 10-Year Prospective Study of Nucleos(t)ide Analogue Therapy for Chronic Hepatitis B. J Clin Transl Hepatol 2020;8:377-84. [PMID: 33447520 DOI: 10.14218/JCTH.2020.00039] [Reference Citation Analysis]
497 Sobhonslidsuk A, Wanichanuwat J, Numthavaj P, Sophonsritsuk A, Petraksa S, Pugasub A, Jittorntam P, Kongsomgan A, Roytrakul S, Phakdeekitcharoen B. Nucleotide Analogue-Related Proximal Renal Tubular Dysfunction during Long-Term Treatment of Chronic Hepatitis B: A Cross-Sectional Study. Gastroenterol Res Pract 2016;2016:2952635. [PMID: 27872640 DOI: 10.1155/2016/2952635] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
498 Takeda H, Takai A, Inuzuka T, Marusawa H. Genetic basis of hepatitis virus-associated hepatocellular carcinoma: Linkage between infection, inflammation, and tumorigenesis. J Gastroenterol. 2017;52:26-38. [PMID: 27714455 DOI: 10.1007/s00535-016-1273-2] [Cited by in Crossref: 45] [Cited by in F6Publishing: 44] [Article Influence: 9.0] [Reference Citation Analysis]
499 李岩, 阚志超, 韩涛. 拉米夫定联合TACE治疗原发性肝癌合并肝硬化30例. 世界华人消化杂志 2008; 16(15): 1700-1703 [DOI: 10.11569/wcjd.v16.i15.1700] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
500 Tawada A, Kanda T, Imazeki F, Yokosuka O. Prevention of hepatitis B virus-associated liver diseases by antiviral therapy. Hepatol Int 2016;10:574-93. [PMID: 27026375 DOI: 10.1007/s12072-016-9720-y] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 2.4] [Reference Citation Analysis]
501 Chau GY. Resection of hepatitis B virus-related hepatocellular carcinoma: Evolving strategies and emerging therapies to improve outcome. World J Gastroenterol 2014; 20(35): 12473-12484 [PMID: 25253947 DOI: 10.3748/wjg.v20.i35.12473] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
502 Yuan G, Hu C, Zhou Y, Liu J, Huang H, Li Y, Yang D, Zhou F, Zhang YY, Zhou Y. A different inhibitor is required for overcoming entecavir resistance: a comparison of four rescue therapies in a retrospective study. Br J Clin Pharmacol 2017;83:2259-65. [PMID: 28511283 DOI: 10.1111/bcp.13330] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
503 Engell CA, Pham VP, Holzman RS, Aberg JA. Virologic Outcome of Using Tenofovir/Emtricitabine to Treat Hepatitis B in HIV-Coinfected Patients. ISRN Gastroenterol 2011;2011:405390. [PMID: 21991507 DOI: 10.5402/2011/405390] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
504 Sagnelli C, Sagnelli E. Towards the worldwide eradication of hepatitis B virus infection: A combination of prophylactic and therapeutic factors. World J Clin Infect Dis 2019; 9(2): 11-22 [DOI: 10.5495/wjcid.v9.i2.11] [Cited by in CrossRef: 1] [Article Influence: 0.5] [Reference Citation Analysis]
505 Liu C, Ye J, Jia H, Zhang M, Han H, Chen F, Chen C. Entecavir and lamivudine therapy for severe acute chronic hepatitis B. Exp Ther Med. 2013;5:545-548. [PMID: 23403957 DOI: 10.3892/etm.2012.850] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
506 Baran B. Nucleos(t)ide analogs in the prevention of hepatitis B virus related hepatocellular carcinoma. World J Hepatol 2015; 7(13): 1742-1754 [PMID: 26167247 DOI: 10.4254/wjh.v7.i13.1742] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
507 Song JE, Lee CH, Kim BS. Efficacy of long-term tenofovir disoproxil fumarate therapy in chronic hepatitis B patients with partial virologic response in real practice. Korean J Intern Med. 2019;34:802-810. [PMID: 30959583 DOI: 10.3904/kjim.2019.037] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
508 Fitzgerald S, Chao J, Feferman Y, Perumalswami P, Sarpel U. Hepatitis B and Hepatocellular Carcinoma Screening Practices in Chinese and African Immigrant-Rich Neighborhoods in New York City. J Racial Ethn Health Disparities. 2016; Epub ahead of print. [PMID: 27797012 DOI: 10.1007/s40615-016-0296-y] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
509 Chen EQ, Wang LC, Lei J, Xu L, Tang H. Meta-analysis: adefovir dipivoxil in combination with lamivudine in patients with lamivudine-resistant hepatitis B virus. Virol J. 2009;6:163. [PMID: 19818142 DOI: 10.1186/1743-422x-6-163] [Cited by in Crossref: 35] [Cited by in F6Publishing: 23] [Article Influence: 2.9] [Reference Citation Analysis]
510 白松林, 扈晓宇, 余颜. 温肾方免煎剂联合拉米夫定治疗HBeAg阳性慢性乙型肝炎脾肾阳虚证的疗效时间关系. 世界华人消化杂志 2013; 21(12): 1126-1130 [DOI: 10.11569/wcjd.v21.i12.1126] [Reference Citation Analysis]
511 Jin YJ, Kim KM, Yoo DJ, Shim JH, Lee HC, Chung YH, Lee YS, Suh DJ. Clinical course of chronic hepatitis B patients who were off-treated after lamivudine treatment: analysis of 138 consecutive patients. Virol J. 2012;9:239. [PMID: 23078793 DOI: 10.1186/1743-422x-9-239] [Cited by in Crossref: 15] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
512 Hsu CW, Liang KH, Lin CL, Wang TH, Yeh CT. Platelet counts modulate the quantitative relationship between hepatitis B viral DNA and surface antigen concentrations: a cross-sectional study of hematological, histological and viral factors. BMC Infect Dis 2017;17:9. [PMID: 28056849 DOI: 10.1186/s12879-016-2121-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
513 Libbrecht E, Doutreloigne J, Van De Velde H, Yuen MF, Lai CL, Shapiro F, Sablon E. Evolution of primary and compensatory lamivudine resistance mutations in chronic hepatitis B virus-infected patients during long-term lamivudine treatment, assessed by a line probe assay. J Clin Microbiol 2007;45:3935-41. [PMID: 17913933 DOI: 10.1128/JCM.00020-07] [Cited by in Crossref: 24] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
514 Blumberg BS. Primary and secondary prevention of liver cancer caused by HBV. Front Biosci (Schol Ed). 2010;2:756-763. [PMID: 20036981 DOI: 10.2741/s98] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
515 Wong GL, Chan HL. Predictors of treatment response in chronic hepatitis B. Drugs. 2009;69:2167-2177. [PMID: 19852523 DOI: 10.2165/11319850-000000000-00000] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 2.6] [Reference Citation Analysis]
516 Puente A, Fortea JI, Cabezas J, Arias Loste MT, Iruzubieta P, Llerena S, Huelin P, Fábrega E, Crespo J. LOXL2-A New Target in Antifibrogenic Therapy? Int J Mol Sci 2019;20:E1634. [PMID: 30986934 DOI: 10.3390/ijms20071634] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 14.0] [Reference Citation Analysis]
517 Kobashi H, Fujioka S, Kawaguchi M, Kumada H, Yokosuka O, Hayashi N, Suzuki K, Okanoue T, Sata M, Tsubouchi H, Sato C, Kiyosawa K, Tanikawa K, Seriu T, Ishikawa H, Takaki A, Iwasaki Y, Osawa T, Takaki T, Sakaguchi K, Shiratori Y, Yamamoto K, Tenney DJ, Omata M. Two cases of development of entecavir resistance during entecavir treatment for nucleoside-naive chronic hepatitis B. Hepatol Int 2009;3:403-10. [PMID: 19669367 DOI: 10.1007/s12072-008-9108-8] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 1.2] [Reference Citation Analysis]
518 Sprinzl MF, Feist C, Koch S, Kremer WM, Lackner KJ, Weinmann A, Galle PR. Cost evaluation of PAGE-B risk score guided HCC surveillance in patients with treated chronic hepatitis B. BMC Health Serv Res 2021;21:846. [PMID: 34419018 DOI: 10.1186/s12913-021-06794-6] [Reference Citation Analysis]
519 Stray SJ, Bourne CR, Punna S, Lewis WG, Finn MG, Zlotnick A. A heteroaryldihydropyrimidine activates and can misdirect hepatitis B virus capsid assembly. Proc Natl Acad Sci U S A 2005;102:8138-43. [PMID: 15928089 DOI: 10.1073/pnas.0409732102] [Cited by in Crossref: 178] [Cited by in F6Publishing: 169] [Article Influence: 11.1] [Reference Citation Analysis]
520 Gordon SC, Lamerato LE, Rupp LB, Li J, Holmberg SD, Moorman AC, Spradling PR, Teshale EH, Vijayadeva V, Boscarino JA, Henkle EM, Oja-Tebbe N, Lu M; CHeCS Investigators. Antiviral therapy for chronic hepatitis B virus infection and development of hepatocellular carcinoma in a US population. Clin Gastroenterol Hepatol 2014;12:885-93. [PMID: 24107395 DOI: 10.1016/j.cgh.2013.09.062] [Cited by in Crossref: 90] [Cited by in F6Publishing: 83] [Article Influence: 11.3] [Reference Citation Analysis]